Hims & Hers Health (HIMS) 10-K27 Feb 232022 FY Annual reportFinancial data

Company Profile

Cover

Cover - USD ($) $ in Millions	12 Months Ended
Cover - USD ($) $ in Millions	Dec. 31, 2022	Feb. 24, 2023	Jun. 30, 2022
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity Registrant Name	HIMS & HERS HEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38986
Entity Tax Identification Number	98-1482650
Entity Address, Address Line One	2269 Chestnut Street, #523
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94123
City Area Code	415
Local Phone Number	851-0195
Title of 12(b) Security	Class A common stock, $0.0001 par value per share
Trading Symbol	HIMS
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 840
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement to be delivered to stockholders in connection with the 2023 annual meeting of stockholders are incorporated by reference in response to Part III of this Annual Report on Form 10-K to the extent stated herein. The 2023 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001773751
Common Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		200,082,691
Common Class V
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		8,377,623

Audit Information

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Firm ID	185
Auditor Location	San Francisco, CA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 46,772	$ 71,784
Short-term investments	132,853	175,490
Inventory	21,562	13,558
Prepaid expenses and other current assets	15,408	9,073
Total current assets	216,595	269,905
Restricted cash	856	856
Goodwill	110,881	110,881
Intangibles, net	21,841	25,890
Operating lease right-of-use assets	4,936	5,111
Other long-term assets	11,232	7,942
Total assets	366,341	420,585
Current liabilities:
Accounts payable	32,363	19,640
Accrued liabilities	12,448	12,194
Deferred revenue	1,472	3,188
Earn-out payable	0	42,834
Operating lease liabilities	1,658	1,365
Total current liabilities	47,941	79,221
Operating lease liabilities	3,649	4,117
Earn-out liabilities	2,975	1,999
Other long-term liabilities	35	629
Total liabilities	54,600	85,966
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 200,051,689 and 196,414,363 shares issued and outstanding as of December 31, 2022 and 2021, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of December 31, 2022 and 2021	21	20
Additional paid-in capital	656,626	613,687
Accumulated other comprehensive loss	(277)	(137)
Accumulated deficit	(344,629)	(278,951)
Total stockholders' equity	311,741	334,619
Total liabilities and stockholders' equity	$ 366,341	$ 420,585

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Common Class A
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	2,750,000,000
Common stock, shares issued (in shares)	200,051,689	196,414,363
Common stock, shares outstanding (in shares)	200,051,689	196,414,363
Common Class V
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.0001
Common stock, shares authorized (in shares)	10,000,000
Common stock, shares issued (in shares)	8,377,623	8,377,623
Common stock, shares outstanding (in shares)	8,377,623	8,377,623

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 526,916	$ 271,878	$ 148,757
Cost of revenue	118,194	67,384	39,307
Gross profit	408,722	204,494	109,450
Operating expenses:
Marketing	272,587	135,902	58,989
Operations and support	77,403	47,593	28,336
Technology and development	29,237	22,379	11,238
General and administrative	98,192	113,662	26,031
Total operating expenses	477,419	319,536	124,594
Loss from operations	(68,697)	(115,042)	(15,144)
Other income (expense):
Change in fair value of liabilities	70	3,802	(3,101)
Other income, net	2,918	445	258
Total other income (expense), net	2,988	4,247	(2,843)
Loss before income taxes	(65,709)	(110,795)	(17,987)
Benefit (provision) for income taxes	31	3,136	(127)
Net loss	(65,678)	(107,659)	(18,114)
Other comprehensive loss	(140)	(126)	(13)
Total comprehensive loss	$ (65,818)	$ (107,785)	$ (18,127)
Net loss per share attributable to common stockholders:
Basic (in USD per share)	$ (0.32)	$ (0.58)	$ (0.51)
Diluted (in USD per share)	$ (0.32)	$ (0.58)	$ (0.51)
Weighted average shares outstanding:
Basic (in shares)	204,516,120	186,781,537	35,353,809
Diluted (in shares)	204,516,120	186,781,537	35,353,809

Consolidated Statements of Mezz

Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Redeemable Convertible Preferred Stock	Redeemable Class A Common Stock
Mezzanine equity, beginning balance (in shares) at Dec. 31, 2019						84,514,191	737,058
Mezzanine equity, beginning balance at Dec. 31, 2019						$ 186,741,000	$ 4,500,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of stock, net of issuance costs (in shares)						7,472,062
Issuance of stock, net of issuance costs						$ 51,900,000
Exercise of Series C redeemable convertible preferred stock warrants (in shares)						1,341,865
Exercise of Series C redeemable convertible preferred stock warrants						$ 11,321,000
Expiration of the Class A common stock redemption right (in shares)							(737,058)
Expiration of the Class A common stock redemption right							$ (4,500,000)
Mezzanine equity, ending balance (in shares) at Dec. 31, 2020						93,328,118	0
Mezzanine equity, ending balance at Dec. 31, 2020						$ 249,962,000	$ 0
Beginning balance (in shares) at Dec. 31, 2019		51,588,459
Beginning balance at Dec. 31, 2019	$ (139,793,000)	$ 5,000	$ 13,378,000	$ 2,000	$ (153,178,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of Class A common stock warrants (in shares)		1,051,206
Exercise of vested stock options (in shares)		167,655
Exercise of Class A common stock warrants	561,000		561,000
Exercise of vested stock options	123,000		123,000
Early exercise of unvested stock options (in shares)		17,924
Vesting of early-exercised stock options	31,000		31,000
Forfeiture of unvested early exercised shares (in shares)		(595,196)
Stock-based compensation	5,831,000		5,831,000
Expiration of the Class A common stock redemption right (in shares)		737,058
Expiration of the Class A common stock redemption right	4,500,000		4,500,000
Other comprehensive loss	(13,000)			(13,000)
Net loss	(18,114,000)				(18,114,000)
Ending balance (in shares) at Dec. 31, 2020		52,967,106
Ending balance at Dec. 31, 2020	(146,874,000)	$ 5,000	24,424,000	(11,000)	(171,292,000)
Increase (Decrease) in Temporary Equity [Roll Forward]
Pre-closing stock repurchase, net of exercise of vested options (in shares)						(206,511)
Pre-closing stock repurchase, net of exercise of vested options						$ (125,000)
Conversion of convertible securities (in shares)						(93,121,607)
Conversion of convertible securities						$ (249,837,000)
Mezzanine equity, ending balance (in shares) at Dec. 31, 2021						0	0
Mezzanine equity, ending balance at Dec. 31, 2021						$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Pre-closing stock repurchase, net of exercise of vested options (in shares)		(1,817,519)
Pre-closing stock repurchase, net of exercise of vested options	(21,902,000)		(21,902,000)
Conversion of redeemable convertible preferred stock to common stock (in shares)		93,121,607
Conversion of redeemable convertible preferred stock to common stock	249,837,000	$ 9,000	249,828,000
Repayment of related-party promissory notes associated with vested shares	854,000		854,000
Forfeiture of related-party promissory notes (in shares)		(370,734)
Conversion of Series D preferred stock warrants to Class A common warrants	1,160,000		1,160,000
Exercise of Class A common stock warrants (in shares)		1,867,380
Exercise of vested stock options (in shares)		1,382,978
Exercise of Class A common stock warrants	21,679,000		21,679,000
Exercise of vested stock options	1,259,000	$ 1,000	1,258,000
Issuance of common stock upon Merger, net of transaction costs (in shares)		24,142,244
Issuance of common stock upon Merger, net of transaction costs	129,659,000	$ 2,000	129,657,000
Issuance of PIPE shares (in shares)		7,500,000
Issuance of PIPE shares	75,000,000	$ 1,000	74,999,000
Warrant expense in connection with Merger	154,000		154,000
Issuance of Merger earn-out shares to common stockholders (in shares)		14,153,520
Issuance of Merger earn-out shares to common stockholders	1,000	$ 1,000
Issuance of common stock for acquisition of businesses (in shares)		8,699,815
Issuance of common stock for acquisition of businesses	52,614,000	$ 1,000	52,613,000
Vesting of early exercised stock options (in shares)		(2,812)
Vesting of early-exercised stock options	227,000		227,000
Stock-based compensation	67,767,000		67,767,000
Issuance of common stock upon vesting of RSUs, net of shares withheld for taxes (in shares)		1,189,786
Payments for taxes related to net share settlement of equity awards	(5,998,000)		(5,998,000)
Issuance of common stock upon Class A common stock warrant redemption (in shares)		1,958,615
Issuance of common stock upon Class A common stock warrant redemption	16,967,000		16,967,000
Other comprehensive loss	(126,000)			(126,000)
Net loss	(107,659,000)				(107,659,000)
Ending balance (in shares) at Dec. 31, 2021		204,791,986
Ending balance at Dec. 31, 2021	334,619,000	$ 20,000	613,687,000	(137,000)	(278,951,000)
Mezzanine equity, ending balance (in shares) at Dec. 31, 2022						0	0
Mezzanine equity, ending balance at Dec. 31, 2022						$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of vested stock options (in shares)		1,611,687
Exercise of vested stock options	2,246,000	$ 1,000	2,245,000
Vesting of early-exercised stock options	197,000		197,000
Stock-based compensation	43,220,000		43,220,000
Issuance of common stock upon vesting of RSUs, net of shares withheld for taxes (in shares)		1,632,111
Payments for taxes related to net share settlement of equity awards	3,901,000
Stock issued during period, shares, employee stock purchase plans (in shares)		393,528
Stock Issued During Period, Value, Employee Stock Purchase Plan	1,178,000		1,178,000
Other comprehensive loss	(140,000)			(140,000)
Net loss	(65,678,000)				(65,678,000)
Ending balance (in shares) at Dec. 31, 2022		208,429,312
Ending balance at Dec. 31, 2022	$ 311,741,000	$ 21,000	$ 656,626,000	$ (277,000)	$ (344,629,000)

Consolidated Statements of Me_2

Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Preferred stock issuance costs	$ 0	$ 12,851
Common stock issuance costs	$ 18,700
Redeemable Convertible Preferred Stock
Preferred stock issuance costs		$ 100

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net loss	$ (65,678,000)	$ (107,659,000)	$ (18,114,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,474,000	4,075,000	1,057,000
Stock-based compensation	42,817,000	67,211,000	5,831,000
Change in fair value of liabilities	(70,000)	(3,802,000)	3,101,000
Warrant expense in connection with Merger	0	154,000	0
Lease termination expense	0	0	754,000
Amortization of debt issuance costs	0	144,000	322,000
Net amortization on securities	146,000	2,166,000	325,000
Benefit for deferred taxes	(594,000)	(3,388,000)	0
Impairment of long-lived assets	1,127,000	0	0
Non-cash operating lease cost	1,605,000	1,510,000	0
Non-cash acquisition-related costs	837,000	1,182,000	0
Non-cash other	0	540,000	59,000
Changes in operating assets and liabilities:
Inventory	(8,004,000)	(9,628,000)	674,000
Prepaid expenses and other current assets	(6,335,000)	3,200,000	(645,000)
Other long-term assets	17,000	(58,000)	8,000
Accounts payable	12,723,000	9,853,000	826,000
Accrued liabilities	909,000	197,000	2,423,000
Deferred revenue	(1,716,000)	1,412,000	519,000
Operating lease liabilities	(1,605,000)	(1,521,000)	0
Earn-out payable	(10,184,000)	0	0
Other long-term liabilities	0	0	381,000
Net cash used in operating activities	(26,531,000)	(34,412,000)	(2,479,000)
Investing activities
Purchases of investments	(187,700,000)	(266,633,000)	(95,008,000)
Maturities of investments	194,259,000	158,375,000	47,990,000
Proceeds from sales of investments	35,846,000	3,465,000	11,550,000
Investment in website and mobile application development and internal-use software	(4,533,000)	(4,175,000)	(2,496,000)
Purchases of property, equipment, and intangible assets	(2,714,000)	(832,000)	(1,737,000)
Deferred consideration paid for acquisitions	(459,000)	0	0
Acquisition of businesses, net of cash acquired	0	(46,468,000)	0
Net cash provided by (used in) investing activities	34,699,000	(156,268,000)	(39,701,000)
Financing activities
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	0	0	51,900,000
Pre-closing stock repurchase	0	(22,027,000)	0
Proceeds from issuance of common stock upon Merger	0	197,686,000	0
Proceeds from PIPE	0	75,000,000	0
Payments for transaction costs related to securities issuances	0	(12,851,000)	(3,356,000)
Proceeds from repayment of promissory notes associated with vested and unvested shares	0	1,193,000	0
Proceeds from exercise of Series C preferred stock warrants	0	0	29,000
Proceeds from exercise of Class A common stock warrants, net of redemption payments	0	787,000	561,000
Proceeds from exercise of vested and unvested stock options, net of repurchases and cancelations	2,246,000	1,253,000	123,000
Repayments of principal on term loan	0	0	(1,515,000)
Payments for taxes related to net share settlement of equity awards	(3,901,000)	(5,998,000)	0
Payments for earn-out consideration for acquisitions	(32,650,000)	0	0
Proceeds from employee stock purchase plan	1,178,000	0	0
Net cash (used in) provided by financing activities	(33,127,000)	235,043,000	47,742,000
Foreign currency effect on cash and cash equivalents	(53,000)	(73,000)	(9,000)
(Decrease) increase in cash, cash equivalents, and restricted cash	(25,012,000)	44,290,000	5,553,000
Cash, cash equivalents, and restricted cash at beginning of period	72,640,000	28,350,000	22,797,000
Cash, cash equivalents, and restricted cash at end of period	47,628,000	72,640,000	28,350,000
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	46,772,000	71,784,000	27,344,000
Restricted cash	856,000	856,000	1,006,000
Total cash, cash equivalents, and restricted cash	47,628,000	72,640,000	28,350,000
Supplemental disclosures of cash flow information
Cash paid for taxes	636,000	338,000	221,000
Cash paid for interest	0	0	10,000
Non-cash investing and financing activities
Expiration of Class A common stock redemption right	0	0	4,500,000
Exercise of convertible preferred stock warrants	0	0	11,292,000
Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase	0	125,000	0
Conversion of redeemable convertible preferred stock to common stock	0	249,837,000	0
Assumption of Merger warrants liability	0	51,814,000	0
Redemption/exercise of Class A common stock warrants	0	37,834,000	0
Conversion of Series D preferred stock warrants to Class A common warrants	0	1,160,000	0
Right-of-use asset obtained in exchange for lease liability	1,206,000	0	0
Vesting of early-exercised stock options, net of cancelations	197,000	227,000	31,000
Common stock issued, contingent consideration, and liabilities assumed in acquisition of businesses	$ 0	$ 99,958,000	$ 0

Organization

Organization	12 Months Ended
Organization	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Hims & Hers Health, Inc. (the “Company” or “Hims & Hers”), incorporated in Delaware and formerly known as Oaktree Acquisition Corp. (“OAC”), is a consumer-first platform transforming the way customers fulfill their health and wellness needs. The Company’s mission is to help the world feel great through the power of better health. The Hims & Hers platform includes access to a highly-qualified and technologically-capable provider network, a clinically-focused electronic medical record system, digital prescriptions, and cloud pharmacy fulfillment. The Company’s digital platform enables access to treatments for a broad range of conditions, including those related to sexual health, hair loss, dermatology, mental health, and primary care. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies on a subscription basis, making accessing treatments simple, affordable, and straightforward. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. In addition, the Company also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. The Company’s products and services are available for purchase directly by customers on the Company’s websites and mobile applications. Additionally, Hims & Hers products can be found in tens of thousands of top retail locations in the United States. On January 20, 2021 (the “Closing Date”), OAC completed the acquisition of Hims, Inc. (“Hims”) pursuant to the Agreement and Plan of Merger dated as of September 30, 2020 (the “Merger Agreement”) by and among OAC, Hims, and Rx Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of OAC (“Merger Sub”). The Merger Agreement provided for, among other things, the combination of Hims and OAC pursuant to the merger of Merger Sub with and into Hims, with Hims continuing as the surviving entity and as a wholly-owned subsidiary of OAC, which changed its name to Hims & Hers Health, Inc. (the “Merger”). The Merger was accounted for as a reverse recapitalization with Hims as the accounting acquirer and OAC as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the consolidated financial statements represents the accounts of Hims and its wholly-owned subsidiaries as if Hims is the predecessor to the Company. The share and per share information in these consolidated financial statements has therefore been retroactively restated to reflect the share exchange ratio established in the Merger (0.4530 shares of Company Class A common stock for 1 share of Hims Class A common stock). Prior to the Merger, OAC ordinary shares and warrants were traded on the New York Stock Exchange (“NYSE”) under the ticker symbols “OAC” and “OAC WS”, respectively. On the Closing Date, the Company’s Class A common stock and warrants began trading on the NYSE under the ticker symbols “HIMS” and “HIMS WS”, respectively. Upon the completion of the warrant redemption in August 2021, the Company is trading on the NYSE solely under the ticker symbol “HIMS”. One of the primary purposes of the Merger was to provide a platform for Hims to gain access to the U.S. capital markets. See Note 3 – Recapitalization for additional details.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities for which it is the primary beneficiary. All intercompany transactions and balances have been eliminated in the consolidated financial statements herein. For the years ended December 31, 2022, 2021, and 2020, the Company had operations primarily in the United States and immaterial operations in the United Kingdom. Reclassifications Beginning with the year ended December 31, 2022, the Company voluntarily reclassified certain operating expenses within the consolidated statements of operations and comprehensive loss. Prior period amounts have been reclassified to conform to this presentation. These changes have no impact on the Company’s previously reported financial position or results of operations. These classification changes are related to breaking out the Company’s previous selling, general, and administrative caption into three new captions entitled: (i) operations and support, (ii) technology and development, and (iii) general and administrative. The operations and support caption includes costs related to the Company’s supply chain, fulfillment and customer support functions. The technology and development caption includes costs related to the operation and enhancement of the Company’s digital platform and product development. The general and administrative caption includes costs relating to the Company’s corporate functions, including personnel costs, professional services, insurance, depreciation and amortization relating to corporate operating activities, and other general corporate costs. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates, judgements, and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation of contingent consideration in business combinations, purchase price allocation for business combinations, estimates used in the capitalization of website and mobile application development and internal-use software costs, and judgements relating to impairment triggering events for long-lived assets. Management believes that the estimates, judgments, and assumptions upon which it relies are reasonable based upon information available to it at the time that these estimates, judgments, and assumptions were made. Actual results experienced by the Company may differ from management’s estimates. To the extent that there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected. Risks and Uncertainties The Company’s business, operations, and financial results are subject to various risks and uncertainties, including adverse United States economic conditions, legal restrictions, changing laws for medical services and prescription products, decisions to outsource or modify portions of its supply chain, and competition in its industry, and of which could adversely affect its business, financial condition, results of operations, and cash flows. These significant factors, among others, could cause the Company’s future results to differ materially from the consolidated financial statements. Concentration Risk The Company’s financial instruments that are potentially exposed to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, investments, and accounts receivable. The Company maintains its cash, cash equivalents, short-term investments, and restricted cash with high-quality financial institutions with investment-grade ratings. The majority of the cash balances are with U.S. banks and are insured to the extent defined by the Federal Deposit Insurance Corporation. The prescription products ordered on the Company’s e-commerce online platform are primarily fulfilled by five affiliated and partner pharmacies. If any of the pharmacies were to stop fulfilling orders, it could significantly slow prescription product sales until fulfillment volume is redistributed to other operating pharmacies. The Company maintains agreements with these pharmacies and is investing in expanding affiliated pharmacy fulfillment capabilities to mitigate any such risk. As of December 31, 2022, two wholesale customers individually represented more than 10% of accounts receivable. As of December 31, 2021, three wholesale customers represented more than 10% of accounts receivable. For the years ended December 31, 2022, 2021, and 2020, no single customer represented more than 10% of revenue. In addition, revenue related to sales in foreign countries was less than 10% of revenue for each of those years. Foreign Currency Translation The Company’s consolidated financial statements are presented in U.S. dollars. Adjustments resulting from translating foreign functional currency financial statements into U.S. dollars are presented as foreign currency translation adjustments, a component of other comprehensive loss on the consolidated statements of operations and comprehensive loss. Business Combinations The Company accounts for its business combinations using the acquisition method of accounting. The purchase price is attributed to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of acquisition. When the Company issues stock-based or cash awards to an acquired company’s shareholders, the Company evaluates whether the awards are consideration or compensation for post-acquisition services. The evaluation includes, among other things, whether the vesting of the awards is contingent on the continued employment of the acquired company’s stockholders beyond the acquisition date. If continued employment is required for vesting, the awards are treated as compensation for post-acquisition services and recognized as expense over the requisite service period. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain assumed obligations. Any acquired assets from a business combination including intangible assets subject to amortization are continuously monitored and reviewed for potential impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. Segment Reporting The Company is managed as a single operating segment on a consolidated basis, inclusive of acquisitions. The Company determined that the Chief Executive Officer (“CEO”) is the chief operating decision maker as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions and managing the organization at a consolidated level. Cash, Cash Equivalents, and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity or remaining maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash and cash equivalents with financial institutions. The restricted cash balance comprises cash collateral that is held by the Company’s primary financial institution to secure a letter of credit issued as a security deposit for the Company’s warehouse facility in New Albany, Ohio. Investments Available-for-sale debt instruments with original maturities at the date of purchase greater than three months and remaining maturities of less than one year are classified as short-term investments. Available-for-sale debt instruments with original maturities at the date of purchase and remaining maturities of greater than one year are classified as long-term investments. The Company intends to sell such investments, if any, at or close to maturity. The investments are designated as available-for-sale and are reported at fair value, with unrealized gains and losses, net of tax, recorded in other comprehensive loss on the consolidated statements of operations and comprehensive loss, except for other-than-temporary impairments and credit losses. The Company determines the cost of the investment sold based on specific identification at the individual security level. The Company records the interest income and realized gains and losses on the sale of these instruments within other income (expense), net on the consolidated statements of operations and comprehensive loss. Other-Than-Temporary Impairment and Credit Losses Prior to 2021, the Company followed the guidance in Accounting Standards Codification (“ASC”) Topic 320, Investments – Debt and Equity Securities in determining whether unrealized losses were other than temporary. The Company adopted ASC Topic 326 for the year ended December 31, 2021, and now considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company’s available-for-sale securities for the years ended December 31, 2022, 2021, or 2020 were caused by fluctuations in market value and interest rates as a result of the economic environment. The Company concluded that an allowance for credit losses was unnecessary as of December 31, 2022 and 2021 and that there were no impairments as of December 31, 2020 considered as other-than-temporary because the decline in the market value was attributable to changes in market conditions and not credit quality, and that it is neither management’s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. There was no realized gain or loss on available-for-sale securities in the periods presented. Fair Value of Financial Instruments The fair value of a financial instrument is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities subject to ongoing fair value measurement are categorized and disclosed into one of the three categories depending on observable or unobservable inputs employed in the measurement. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. • Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Inventory Inventory primarily consists of finished goods and raw materials that are located at Company-managed and third-party fulfillment warehouses and pharmacies. Inventory is stated at the lower of cost and net realizable value and inventory cost is determined by the weighted average cost method. The Company reserves for expired, slow-moving, and excess inventory by estimating the net realizable value based on the potential future use of such inventory. Management monitors inventory to identify events that would require impairment due to slow-moving, expired, or obsolete inventory and reduces the value of inventory when required. Obsolete inventory balances are written off against the inventory allowance when management determines that the inventory cannot be sold. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of balances related to prepayments or vendor deposits for insurance, marketing, software, inventory and other operating costs, and trade and other accounts receivables. Prepaid expenses are recorded when payment has been made in advance for goods and services. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Receivables are stated at amounts estimated by management to be equal to their net realizable values. The allowance for doubtful accounts is the Company's best estimate of the amount of expected credit losses. The expectation of collectability is based on the Company's review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and an allowance is recorded accordingly. Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of December 31, 2022 and 2021, accounts receivable was $3.9 million and $4.1 million, respectively. There were no write-offs of accounts receivable for the years ended December 31, 2022, 2021, or 2020. As of December 31, 2022 and 2021, the Company had no allowances for doubtful accounts. The Company does not have any off-balance sheet credit exposure related to its customers. Other Long-Term Assets Property and equipment, net was $3.0 million and $2.2 million as of December 31, 2022 and 2021, respectively, and is classified within other long-term assets on the consolidated balance sheets. Property and equipment are recorded at cost, less accumulated depreciation and amortization. Maintenance and repair costs are charged to expense as incurred, and expenditures that extend the useful lives of assets are capitalized. Property and equipment are depreciated or amortized using the straight-line method over the estimated useful lives ranging from two Capitalizable website and mobile application development and internal-use software costs, net was $8.2 million and $5.7 million as of December 31, 2022 and 2021, respectively, and is classified within other long-term assets on the consolidated balance sheets. The costs incurred during the website application and infrastructure stages as well as costs incurred during the graphics and content development stages are capitalized; all other costs are expensed as incurred. In addition, the Company incurs costs to develop software for internal use. The costs incurred during the application development phase are capitalized until the project is completed and the asset is ready for intended use. All costs that relate to the preliminary project and post-implementation operation phases of development are expensed as incurred. The following table summarizes the estimated amortization of website development and internal-use software costs subsequent to December 31, 2022 (in thousands): 2023 $ 3,760 2024 2,892 2025 1,528 Total $ 8,180 Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually in the fourth quarter or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company operates as one reporting unit. When testing goodwill for impairment, the Company may first perform an optional qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company will recognize an impairment loss in an amount equal to that excess but limited to the total amount of goodwill. Goodwill of $110.9 million was acquired during the second and third quarters of 2021 and no goodwill impairment was recorded for the years ended December 31, 2022 and 2021. Intangible Assets Intangible assets primarily includes trade name, customer relationships, and developed technology. The Company amortizes such definite-lived intangible assets on a straight-line basis over the assets’ estimated useful lives of two Impairment of Long-Lived Assets Long-lived assets include property and equipment, website and mobile application development and internal-use software, and intangible assets subject to amortization. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. As of December 31, 2021 and 2020, the Company determined that no events or changes in circumstances existed that would indicate any impairment of its long-lived assets. The Company recognized $1.1 million of impairment charges on long-lived assets during the year ended December 31, 2022 in general and administrative expenses on the consolidated statements of operations and comprehensive loss. Operating Leases The Company determines if an arrangement contains a lease at inception based on whether there is identified property, plant, or equipment and whether the Company controls the use of the identified asset throughout the period of use. The Company leases two real estate facilities under non-cancelable operating leases with expiration dates in fiscal years 2025 and 2027. The Company's operating leases are reflected in the operating lease right-of-use (“ROU”) assets and in the operating lease liabilities in the accompanying consolidated balance sheets. The operating lease ROU assets represent the Company’s right to use the underlying assets for the lease terms and the lease liabilities represent the Company’s obligation to make lease payments arising from the leases. The operating lease ROU assets and lease liabilities are recognized at each lease’s inception date based on the present value of lease payments over the lease term discounted based on the more readily determinable of (i) the rate implicit in the lease or (ii) the Company’s incremental borrowing rate, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease. Because the Company’s operating leases do not provide an implicit rate, the Company estimates its incremental borrowing rate at the lease commencement date for borrowings with a similar term. The Company’s operating lease ROU assets are measured based on the corresponding operating lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. The Company does not assume renewals or early terminations unless it is reasonably certain to exercise these options at commencement. The Company does not allocate consideration between lease and non-lease components. The Company's lease agreements contain variable costs such as common area maintenance, operating expenses, or other costs. Variable lease payments are recognized in the period in which the obligation for those payments are incurred. In addition, the Company does not recognize ROU assets or operating lease liabilities for leases with a term of 12 months or less of all asset classes. Operating lease expense is recognized on a straight-line basis over each lease term. Revenue Recognition The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. The Company’s consolidated revenue primarily comprises online sales of health and wellness products and services through the Company’s websites and mobile applications, including prescription and non-prescription products. In contracts that contain prescription products issued as the result of a consultation, revenue also includes medical consultation services provided by Affiliated Medical Groups (defined below). Additionally, the Company offers a range of health and wellness products through wholesale partners. Revenue consists of the following (in thousands): Year Ended December 31, 2022 2021 2020 Online Revenue $ 502,507 $ 259,170 $ 140,728 Wholesale Revenue 24,409 12,708 8,029 Total revenue $ 526,916 $ 271,878 $ 148,757 For Online Revenue, the Company defines its customer as an individual who purchases products or services through its websites or mobile applications. For Wholesale Revenue, the Company defines its customer as a wholesale partner, with the exception of consignment arrangements, where its customer is defined as an individual who purchases products through certain third-party platforms. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills and contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically within one day. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus estimates. For each of the years ended December 31, 2022, 2021, and 2020, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups,” which are professional corporations or other professional entities owned by licensed physicians and that engage licensed healthcare professionals (physicians, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 11 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, in its sole discretion, sets all listed prices charged on its websites and mobile applications for products and services. Additionally, to fulfill its promise to customers for contracts that include sale of prescription products, the Company maintains relationships with (i) certain third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) and (ii) XeCare, LLC (“XeCare”) and Apostrophe Pharmacy LLC (“Apostrophe Pharmacy”, and together with XeCare, the “Affiliated Pharmacies”), which are licensed mail order pharmacies providing prescription fulfillment solely to the Company’s customers. The Partner Pharmacies and the Affiliated Pharmacies fill prescription orders for customers who have received a prescription from a prescribing Provider through the Company’s websites and mobile applications. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy or Affiliated Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies and Affiliated Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, in its sole discretion, sets all listed prices charged on its websites and mobile applications for products and services. The Company estimates refunds using the expected value method primarily based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. For online sales, payment for prescription medication and non-prescription products is typically collected from the customer a few days in advance of product shipment. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the consolidated balance sheets since the associated revenue will be primarily recognized within the following month. For wholesale arrangements, payments are collected in accordance with contract terms. Cost of Revenue Cost of revenue consists of costs directly attributable to the products shipped and services rendered, including product costs, packaging materials, shipping costs, and labor costs directly related to revenue generating activities. Costs related to free products where there is no expectation of future purchases from a customer and depreciation and amortization on property and equipment are considered to be operating expenses and are excluded from cost of revenue. Stock-Based Compensation The fair value of stock options, equity-classified warrants issued to vendors, and restricted stock units (“RSUs”), are measured at the grant date fair value. The fair value of employee stock options and vendor warrants are generally determined using the Black-Scholes Merton (“BSM”) option-pricing model using various inputs, including estimates of expected volatility, term, risk-free rate, and future dividends. Stock options that were granted to the Company’s CEO with performance and market conditions and earn-out RSUs were valued using the Monte Carlo simulation model. The Company recognizes compensation costs on a straight-line basis over the requisite service period of the employee and vendor, which is generally the vesting term of four years for options, warrants, and RSUs that do not have performance or market conditions. Stock options and RSUs with performance conditions are recognized when it is probable that performance criteria will be achieved and compensation cost is recognized using the accelerated attribution method. The Company accounts for forfeitures as they occur. The Company’s Employee Stock Purchase Plan (“ESPP”) permits eligible employees to purchase the Company’s Class A common stock during pre-specified offering periods at a discount established by the compensation committee. The purchase price is 85% of the lower of the fair market value of the Company’s Class A common stock on the first trading day of the offering period and the fair market value on the purchase date. The ability to purchase shares of the Company’s Class A common stock for a discount represents an option and, therefore, the ESPP is considered a compensatory plan. Accordingly, stock-based compensation expense is determined based on the option’s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the requisite service period, which is the withholding period. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax reporting basis of assets and liabilities. These differences are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company recognizes the effect on deferred income taxes of a change in tax rates in the period that includes the enactment date. The Company provides a valuation allowance, if necessary, to reduce its deferred tax assets to the net amount it believes is more likely than not to be realized. The Company considers both positive and negative evidence, including its historical operating results, forecasts of future taxable income on a jurisdiction-by-jurisdiction basis, and ongoing tax planning strategies, to ascertain the need for a valuation allowance. In the event the Company determines that i

Recapitalization

Recapitalization	12 Months Ended
Recapitalization	Dec. 31, 2022
Reverse Recapitalization [Abstract]
Recapitalization	RecapitalizationAs discussed in Note 1 – Organization, on the Closing Date, OAC completed the acquisition of Hims and acquired 100% of Hims’ shares and Hims received gross proceeds of $197.7 million. Transaction costs of $18.7 million, which consist of legal, accounting, and other professional services directly related to the Merger, are included in additional paid-in capital on the consolidated balance sheet. On the Closing Date, each Hims stockholder received approximately 0.4530 shares of the Company’s Class A common stock, par value $0.0001 per share, for each share of Hims Class A common stock, par value $0.000001 per share, that such stockholder owned (with the CEO receiving 0.4530 shares of the Company’s Class V common stock, par value $0.0001 per share, for each share of Hims Class V common stock, par value $0.000001 per share, that the CEO owned). Each Hims stockholder also received 0.0028 warrants exercisable for the Company’s Class A common stock, for each share of Hims Class A or Class V common stock owned by such stockholder prior to the Merger and earn-out shares at an exchange ratio of 0.0443. As additional consideration, OAC also granted 888,143 OAC Class A common stock warrants (“Parent Warrants”) to Hims’ stockholders, 3,443 Parent Warrants to warrant holders, and approximately 35,000 RSUs to Hims’ option and RSU holders (“Parent Warrant RSUs”). All equity awards of Hims were assumed by OAC and converted into comparable equity awards that are settled or exercisable for shares of the Company’s Class A common stock. As a result, each stock option was converted into an option to purchase shares of the Company’s Class A common stock based on an exchange ratio of 0.4530. Each award of the Hims’ RSUs was converted into RSUs of the Company based on an exchange ratio of 0.4530. Similarly, all outstanding Hims warrants were converted at an exchange ratio of 0.4530. The Merger was accounted for as a reverse recapitalization with Hims as the accounting acquirer and OAC as the acquired company for accounting purposes. Hims was determined to be the accounting acquirer since Hims’ shareholders prior to the Merger had the greatest voting interest in the combined entity, Hims’ shareholders appointed the initial directors of the combined Board of Directors and control future appointments, Hims comprises all of the ongoing operations, and Hims’ senior management directs operations of the combined entity. Accordingly, all historical financial information presented in these consolidated financial statements represents the accounts of Hims and its wholly-owned subsidiaries as if Hims, rather than OAC, is the predecessor to the Company. No step-up basis of intangible assets or goodwill was recorded and net assets were stated at historical cost consistent with the treatment of the transaction as a reverse recapitalization of Hims. The shares and net loss per common share prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger (0.4530 Company shares for 1 Hims share). Merger Earn-Out Shares Following the closing of the Merger, holders of Hims’ common stock and outstanding equity awards (including warrant, stock option and RSU holders) had the right to receive up to an aggregate amount of 16,000,000 shares of Company Class A common stock (or equivalent equity award) that would vest (in part) in equal thirds if the trading price of the Company’s Class A common stock was greater than or equal to $15.00, $17.50, and $20.00 for any 10 trading days within any 20-trading day period on or prior to the date that is five years following the Closing Date. These shares of restricted Class A common stock and equivalent equity awards would also vest in connection with an acquisition of the Company if the applicable thresholds were met in any sale (as defined in the Merger Agreement) but subject to the same five-year deadline. In February 2021, all earn-out thresholds were met. In the first quarter of 2021, earn-out awards related to option holders received final approval by the Board of Directors. The earn-out shares are equity classified since they do not meet the liability classification criteria outlined in ASC 480, Distinguishing Liabilities from Equity and are both (i) indexed to the Company’s own shares and (ii) meet the criteria for equity classification. PIPE Investment Concurrently with the execution of the Merger Agreement, OAC entered into subscription agreements on September 30, 2020 with certain investors (the “PIPE Investors”) pursuant to which such investors collectively subscribed for 7,500,000 shares of the Company’s Class A common stock at $10.00 per share for aggregate gross proceeds of $75.0 million (the “PIPE Investment”). The PIPE Investment was consummated substantially concurrently with the closing of the Merger.

Acquisitions

Acquisitions	12 Months Ended
Acquisitions	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions The Company completed two acquisitions in 2021 and accounted for these transactions using the acquisition method with the purchase prices being allocated to tangible and identifiable intangible assets acquired and liabilities assumed based on their respective estimated fair values on the acquisition dates. Fair values were determined using income approaches. Honest Health Limited In June 2021, the Company acquired all of the outstanding equity of Honest Health Limited, which is now Hims & Hers UK Limited (“HHL”), an entity located in the United Kingdom that offers health and wellness products and services, to further expand its operations in the United Kingdom. The purchase price for accounting purposes was $4.8 million, including cash paid upfront and payable in the future, an aggregate of 624,880 shares of the Company’s Class A common stock valued at $1.9 million, and contingent consideration of $1.2 million. The purchase agreement includes up to $10.0 million of potential earn-out payable in cash and stock upon achievement of revenue targets, which is recognized as contingent consideration as well as post-acquisition employment expense. The purchase price for accounting purposes excludes stock and cash consideration to be paid by the Company that is subject to vesting, which is recognized as selling, general, and administrative expenses post-acquisition. See Note 14 – Stockholders’ Equity for additional details. The Company also incurred acquisition costs of $1.9 million directly related to the acquisition, as well as post-acquisition employment expense of $0.7 million, which were recorded within selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss. The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 1,470 Other intangible assets 570 Goodwill 2,739 Other net assets 24 Net assets acquired $ 4,803 The excess of the consideration paid over the fair value of the net assets acquired is recorded as goodwill. The acquired goodwill of $2.7 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recognized upon acquisition is not expected to be deductible for U.S. or U.K. income tax purposes. The pro forma financial information, assuming the acquisition had taken place on January 1, 2020, as well as the revenue and earnings generated during the period after the acquisition date, were not material for separate disclosure and, accordingly, have not been presented. Apostrophe In July 2021, the Company acquired all of the outstanding equity of YoDerm, Inc. (“Apostrophe”) , an entity located in the United States that offers health and wellness products and services. The purchase price for accounting purposes was $131.6 million, including cash payments of $48.2 million, an aggregate of 8,074,935 shares of the Company’s Class A common stock valued at $50.7 million, and contingent consideration of $32.7 million. The purchase agreement includes up to $50.0 million of potential earn-out payable in cash upon achievement of revenue targets, which is recognized as contingent consideration or post-acquisition employment expense depending on whether the vesting is contingent on continued employment beyond the acquisition date. The purchase price for accounting purposes excludes stock consideration issued by the Company that is subject to vesting, which is recognized as selling, general, and administrative expenses post-acquisition. See Note 14 – Stockholders’ Equity for additional details . The Company also incurred acquisition costs of $5.0 million directly related to the acquisition, as well as post-acquisition employment expense of $0.5 million, which were recorded within selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss. The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 22,700 Other intangible assets 3,140 Goodwill 108,142 Other net liabilities (2,346) Net assets acquired $ 131,636 The fair value measurements of the identified intangible assets were based primarily on significant unobservable inputs and thus represent a Level 3 measurement as defined in ASC 820. The fair values of trade name and developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets including revenue and cash flow forecasts, customer churn rate, technology life, royalty rate, and discount rate. The fair value of customer relationships was determined using the multi-period excess earnings method which involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets, and then discounting the resulting net cash flows to a present value using an appropriate discount rate. The excess of the consideration paid over the fair value of the net assets acquired is recorded as goodwill. The acquired goodwill of $108.1 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recognized upon acquisition is not expected to be deductible for U.S. income tax purposes. From the acquisition date through December 31, 2021, the Company recognized revenue related to Apostrophe of approximately $11 million. Incremental pro forma revenue attributed to Apostrophe, assuming the acquisition had occurred as of January 1, 2020, would have been approximately $21 million and $13 million for the years ended December 31, 2021 and 2020, respectively. The pro forma revenue is presented for informational purposes only and does not purport to be indicative of the results of future operations or the results that would have occurred had the transaction taken place on January 1, 2020. Pro forma earnings of Apostrophe, assuming the acquisition had occurred as of January 1, 2020, as well as earnings generated during the period after the acquisition date, were not material for separate disclosure and, accordingly, have not been presented.

Investments

Investments	12 Months Ended
Investments	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Short-term investments as of December 31, 2022, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair Corporate bonds $ 99,672 $ — $ (106) $ 99,566 Government and government agency 33,317 17 (47) 33,287 Total short-term investments $ 132,989 $ 17 $ (153) $ 132,853 Short-term investments as of December 31, 2021, consist of the following (in thousands): Adjusted Unrealized Fair Corporate bonds $ 146,032 $ (30) $ 146,002 Asset-backed bonds 29,507 (19) 29,488 Total short-term investments $ 175,539 $ (49) $ 175,490

Inventory

Inventory	12 Months Ended
Inventory	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following (in thousands): December 31, 2022 2021 Finished goods $ 16,477 $ 10,428 Raw materials 5,085 3,130 Total inventory $ 21,562 $ 13,558

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2022 2021 Wholesale trade receivables $ 3,231 $ 3,577 Prepaid expenses 10,392 4,606 Other current assets 1,785 890 Total prepaid expenses and other current assets $ 15,408 $ 9,073

Intangible Assets

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets as of December 31, 2022 consist of the following (in thousands): Gross Accumulated Amortization and Impairment Net Weighted Trade name $ 24,170 $ (4,504) $ 19,666 8.4 Other 4,581 (2,406) 2,175 4.7 Intangible assets, net $ 28,751 $ (6,910) $ 21,841 8.0 Intangible assets as of December 31, 2021 consist of the following (in thousands): Gross Accumulated Net Weighted Trade name $ 24,170 $ (1,298) $ 22,872 9.2 Other 3,846 (828) 3,018 2.4 Intangible assets, net $ 28,016 $ (2,126) $ 25,890 8.4 Amortization expense for intangible assets was $4.1 million, $2.1 million, and less than $0.1 million for the years ended December 31, 2022, 2021, and 2020, respectively. Impairment expense for intangible assets was $0.7 million for the year ended December 31, 2022. There was no impairment expense for the years ended December 31, 2021 and 2020. Amortization that will be charged to expense over the remaining life of the intangible assets subsequent to December 31, 2022 is as follows (in thousands): 2023 $ 3,434 2024 2,694 2025 2,560 2026 2,452 2027 and thereafter 10,701 $ 21,841

Accrued Liabilities

Accrued Liabilities	12 Months Ended
Accrued Liabilities	Dec. 31, 2022
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following (in thousands): December 31, 2022 2021 Payroll $ 4,999 $ 3,363 Marketing 4,990 3,158 Tax 963 954 Professional services 643 734 Product and shipping 263 2,635 Other accruals 590 1,350 Total accrued liabilities $ 12,448 $ 12,194

Operating Leases

Operating Leases	12 Months Ended
Operating Leases	Dec. 31, 2022
Leases [Abstract]
Operating Leases	Operating Leases In January 2020, the Company entered into a 63-month non-cancelable lease for 302,880 square feet of warehouse space in New Albany, Ohio. The lease commenced on June 1, 2020. Total minimum lease payments are $7.9 million, net of rent abatement for an initial three-month period and with an annual escalation of 2.5%. The Company has the option to extend the lease term for a period of five years. The Company utilizes the reasonably certain threshold criteria in determining which options it will exercise. In January 2022, the Company entered into a 62-month non-cancelable lease for 24,465 square feet of warehouse, distribution, and pharmacy space in Gilbert, Arizona. The lease commenced on September 1, 2022. Total minimum lease payments are $1.5 million, net of rent abatement for an initial two-month period and with annual escalation of 3.0%. The Company has the option to extend the lease term for a period of five years. For the years ended December 31, 2022 and 2021, the Company recorded operating lease costs of $1.9 million and $1.8 million, respectively, including variable operating lease costs of $0.3 million in both years. For the years ended December 31, 2022 and 2021, operating cash flows used for operating leases were $1.6 million and $1.5 million, respectively. As of December 31, 2022, the weighted average remaining lease term and weighted average discount rate was 3.2 years and 4.7%, respectively. Future minimum lease payments under the Company's non-cancelable operating lease with an initial lease term in excess of one year subsequent to December 31, 2022 are as follows (in thousands): 2023 $ 1,876 2024 1,924 2025 1,408 2026 303 2027 259 Gross lease payments 5,770 Less: imputed interest (463) Present value of net future minimum lease payments $ 5,307

Variable Interest Entities

Variable Interest Entities	12 Months Ended
Variable Interest Entities	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities The variable interest entities (“VIEs”) are: (i) the Affiliated Medical Groups; and (ii) the Affiliated Pharmacies. The Company determined that it is the primary beneficiary of these entities for accounting purposes because it has the ability to direct the activities that most significantly affect the entities’ economic performance and has the obligation to absorb the losses. Under the VIE model, the Company presents the results of operations, cash flows, and the financial position of the VIEs as part of the consolidated financial statements of the Company as if the consolidated group were a single economic entity. The assets of the VIEs can only be used to settle the obligations of the VIEs. There is no noncontrolling interest upon consolidation of the entities. The results of operations and cash flows of the VIEs are also included in the Company’s consolidated financial statements. As of December 31, 2022 and 2021, the Company’s consolidated balance sheets included current assets of $7.5 million and $2.2 million, respectively, and total assets of $7.7 million and $2.2 million, respectively, for the VIEs. As of December 31, 2022 and 2021, current and total liabilities were $3.7 million and $3.0 million, respectively. All amounts are after elimination of intercompany transactions, balances, and non-cash impact of operating leases. For the years ended December 31, 2022, 2021, and 2020, the VIEs charged the Company $64.2 million, $23.6 million, and $12.0 million, respectively, for services rendered. For the years ended December 31, 2022, 2021, and 2020 operations of the VIEs generated net income of $9.1 million and net losses of $3.3 million, and $1.9 million, respectively, inclusive of administrative expenses.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 24,606 $ — $ — $ 24,606 Government bonds — 11,315 — 11,315 Short-term investments: Corporate bonds — 99,566 — 99,566 Government and government agency — 33,287 — 33,287 Restricted cash: Money market funds 856 — — 856 Total assets $ 25,462 $ 144,168 $ — $ 169,630 Liabilities Earn-out liabilities $ — $ — $ 2,975 $ 2,975 Total liabilities $ — $ — $ 2,975 $ 2,975 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 59,761 $ — $ — $ 59,761 Government bonds — 7,664 — 7,664 Short-term investments: Corporate bonds — 146,002 — 146,002 Government bonds — 29,488 — 29,488 Restricted cash: Money market funds 856 — — 856 Total assets $ 60,617 $ 183,154 $ — $ 243,771 Liabilities Earn-out liabilities $ — $ — $ 1,999 $ 1,999 Total liabilities $ — $ — $ 1,999 $ 1,999 The fair values of cash, accounts receivable, accounts payable, and accrued liabilities approximated their carrying values as of December 31, 2022 and 2021, due to their short-term nature. All other financial instruments, except for earn-out liabilities, are valued either based on recent trades of securities in active markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. During the years ended December 31, 2022, 2021, and 2020, the Company had no transfers between levels of the fair value hierarchy of its assets or liabilities measured at fair value. As of December 31, 2022 and 2021, the long-term earn-out liability, which is solely related to the acquisition of HHL, is classified as a Level 3 fair value measurement containing significant unobservable inputs including estimates of achieving certain revenue targets. At inception, the fair value of the earn-out liability associated with the HHL acquisition was determined based on revenue projections and probability of achievement of revenue targets as evaluated using a Monte Carlo simulation. The following assumptions were used to determine the fair value at inception: HHL Revenue risk-adjusted discount rate 9.1 % Revenue volatility 50.0 % Counterparty discount rate 5.0 % The fair value of the earn-out liability is remeasured at each reporting period. This change in fair value is related to contingent consideration and compensation costs (see Note 14 – Stockholders’ Equity) and is recognized in other income (expense) and general and administrative expenses, respectively, on the consolidated statements of operations and comprehensive loss. The change in the fair value of earn-out liabilities is as follows (in thousands): Balance at December 31, 2020 $ — HHL acquisition 1,208 Apostrophe acquisition 32,650 Change in fair value due to revaluation and service-based vesting 10,975 Reclassification to earn-out payable (42,834) Balance at December 31, 2021 1,999 Change in fair value due to revaluation and service-based vesting 976 Balance at December 31, 2022 $ 2,975

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations The Company has contractual obligations to make future purchases, primarily related to cloud-based software contracts used in operations. As of December 31, 2022, purchase obligations were $1.4 million, with $1.2 million payable in 2023 and $0.2 million payable in 2024. Legal Proceedings From time to time, the Company is a party to various litigation, claims, and other legal and administrative proceedings arising in the ordinary course of business. Some of these claims, lawsuits, and other proceedings may involve highly complex issues that are subject to substantial uncertainties, and could result in damages, fines, penalties, non-monetary sanctions, or relief. Management is not currently aware of any matters that are reasonably likely to have a material adverse impact on the Company’s business, financial position, results of operations, or cash flows.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stockholders' Equity	Stockholders’ Equity Common Stock The Company has two classes of common stock, Class A and Class V common stock. The rights are identical, including liquidation and dividend rights, except Class V common stock has additional voting rights. RSU Releases During the years ended December 31, 2022 and 2021, the Company released 2,333,695 and 1,810,545 gross shares of Class A common stock upon vesting of RSUs. In connection with the releases, 701,584 and 620,759 shares of Class A common stock were withheld for the payment of employee taxes. There were no RSU releases for year ended December 31, 2020. 2017 Stock Plan and 2020 Equity Incentive Plan In July 2017, Hims adopted the 2017 Stock Plan (the “2017 Plan”). Under the 2017 Plan, the board of directors of Hims granted awards, including incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSU awards, and other stock awards to employees, directors, and consultants of Hims. In January 2021, in connection with the Merger, the Board of Directors adopted the 2020 Equity Incentive Plan (the “2020 Plan”) and reserved 21,000,000 authorized shares of Class A common stock the Company could issue. In addition, up to 19,000,000 shares of Hims Class A common stock subject to awards granted under the 2017 Plan that were forfeited, expired, or lapsed unexercised or unsettled could be added to the 2020 Plan reserve. Beginning on January 1, 2022 and ending on January 1, 2031, the number of authorized shares of common stock under the 2020 Plan will automatically increase each fiscal year by 5% of the total number of Class A and Class V common stock issued and outstanding on the last day of the preceding fiscal year unless the Board of Directors approves a lesser number. As of the effective date of the 2020 Plan, no further stock awards have been or will be granted under the 2017 Plan. Through December 31, 2022, 1,862,078 shares of Class A common stock subject to awards granted under the 2017 Plan that were outstanding on the Closing date and forfeited after the adoption of the 2020 Plan were added to the 2020 Plan reserve. Additionally, on January 1, 2022, 10,239,599 shares of Class A common stock were automatically added to the 2020 Plan reserve. Therefore, as of December 31, 2022, there were 33,101,677 shares of Class A common stock reserved and 10,963,031 shares of Class A common stock available for grant under the 2020 Stock Plan. There were no more shares available for grant under the 2017 Plan since the 2017 Plan was replaced by the 2020 Plan. 2020 Employee Stock Purchase Plan In January 2021, the Board of Directors adopted the Company’s Employee Stock Purchase Plan (“ESPP”), which became effective immediately prior to the Closing Date. The total shares of Class A common stock initially reserved under the ESPP is limited to 4,000,000 shares of Class A common stock. Beginning on January 1, 2022 and ending on January 1, 2041 (unless extended by the Board of Directors and approved by the Company’s shareholders), the number of authorized shares of common stock under the ESPP will automatically increase each fiscal year by the lesser of (i) 1% of the total number of Class A and Class V common stock issued and outstanding on the last day of the preceding fiscal year, (ii) 12,000,000 shares of Class A common stock, or (iii) a number of shares of Class A common stock determined by the Board of Directors. On January 1, 2022, 2,047,919 shares of Class A common stock were automatically added to the ESPP reserve. Therefore, as of December 31, 2022, 6,047,919 shares of Class A common stock have been reserved for issuance under the ESPP. During the year ended December 31, 2022, the Company issued 393,528 shares of Class A common stock under the ESPP. No shares were issued under the ESPP during the year ended December 31, 2021. As of December 31, 2022, there were 5,654,391 shares of Class A common stock available for issuance under the ESPP. Under the ESPP, eligible employees may purchase the Company’s Class A common stock during pre-specified offering periods at a discount established by the Company’s compensation committee. The purchase price is 85% of the lower of the fair market value of the Company’s Class A common stock on the first trading day of the offering period or the fair market value on the purchase date. Under the ESPP, the Company may specify offering periods with durations of not more than 27 months, and may specify shorter purchase periods within each offering period. Employees participating in the ESPP commence payroll withholdings that accumulate through the end of the respective offering period. As of December 31, 2022, $0.3 million has been withheld via employee payroll deductions for employees who have opted to participate in the purchase period ending May 2023. Stock Options Options for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date and then 1/48th of the total grant vesting monthly thereafter. Options granted to current employees generally vest 1/48th of the total grant monthly over four years. Options granted are exercisable within a period not exceeding ten years from the grant date. On June 17, 2020, the board of directors of Hims granted 3,246,139 and 1,623,070 stock options to the CEO with an exercise price of $2.43 to vest upon either (i) an acquisition of the Company with per share consideration equal to at least $22.99 and $38.31, respectively, or (ii) a per share price on a public stock exchange that is at least equal to $22.99 and $38.31, respectively. The CEO is required to be employed at the time the per share consideration/price is achieved in order to receive the awards, but the awards are not subject to any other service condition. The Company recognizes expense related to these awards based on the fair value and derived service period as measured using a Monte Carlo simulation model, and the expense is accelerated if the requirements outlined in (i) and (ii) above are achieved. The grant date fair value was $16.6 million for these awards. The $22.99 per share price threshold related to awards for the 3,246,139 stock options was achieved in February 2021 subsequent to the Merger and, therefore, the Company recognized all $11.3 million of expense related to the grant during the three months ended March 31, 2021 due to achievement of the market condition. As of December 31, 2022, there was $1.8 million of remaining compensation expense to be recognized for the remaining 1,623,070 stock options over a period of 1.29 years. On February 24, 2022, the Board of Directors granted 2,085,640 stock options to the CEO with an exercise price of $5.01 that vest in four The grant date fair value of the Company’s stock options granted (excluding the stock options granted to the CEO outlined above) was estimated using the following weighted average assumptions: Year Ended December 31, 2022 2021 2020 Expected term (in years) 6.02 5.94 5.94 Expected volatility 48.0 % 58.6 % 62.3 % Risk-free interest rate 2.0 % 0.9 % 0.5 % Expected dividend yield — % — % — % Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2021 10,401 $ 4.01 7.73 $ 37,868 Granted 6,321 5.10 Exercised (including early exercised options vested during the period) (1,728) 1.42 Forfeited and expired (544) 6.97 Outstanding at December 31, 2022 14,450 4.68 7.98 35,771 Exercisable as of December 31, 2022 8,389 3.81 7.16 28,509 The weighted average grant date fair value of options granted for the years ended December 31, 2022, 2021, and 2020 was $2.44, $6.51, and $3.49 per share, respectively, and the intrinsic value of vested options exercised was $6.3 million, $12.6 million, and $0.7 million, respectively. As of December 31, 2022, there was $22.7 million of unrecognized stock-based compensation related to unvested stock options (excluding the stock options granted to the CEO outlined above) which is expected to be recognized over a weighted average period of 2.65 years. The options outstanding and exercisable as of December 31, 2022 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Shares Weighted $0.06 – 0.40 1,830 5.21 1,830 5.21 1.55 – 1.75 959 6.43 959 6.43 2.43 – 3.11 3,037 7.50 2,921 7.42 5.01 – 6.82 6,190 9.21 977 9.17 8.13 – 9.41 1,569 8.13 1,301 8.04 12.21 – 15.17 865 8.19 401 8.03 14,450 8,389 The options outstanding and exercisable as of December 31, 2021 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Shares Weighted $0.06 – 0.40 2,309 5.64 2,308 5.64 1.55 – 1.75 2,120 7.34 2,006 7.34 2.43 3,242 8.42 3,241 8.42 8.13 – 9.41 1,756 8.82 1,291 8.54 12.21 – 15.17 974 9.28 128 9.02 10,401 8,974 RSUs RSUs for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date on the first Company Quarterly Vesting Date (defined below) and the remaining grant vesting quarterly thereafter on the specified vesting dates of March 15, June 15, September 15, and December 15 (each, a “Company Quarterly Vesting Date” or collectively, “Company Quarterly Vesting Dates”). Additional RSUs granted to current employees generally vest quarterly on Company Quarterly Vesting Dates over four years. RSU activity is as follows (in thousands, except for weighted average grant date fair value): Shares Weighted Average Unvested at December 31, 2021 3,982 $ 11.55 Granted 10,536 4.97 Vested (2,294) 8.86 Forfeited and expired (623) 8.05 Unvested at December 31, 2022 11,601 $ 6.40 Included in the above activity are 476,308 earn-out RSUs and 9,478 Parent Warrant RSUs issued to the CEO as part of the Merger that vest in accordance with the same market conditions as the CEO stock options, of which 317,539 earn-out RSUs and 6,319 Parent Warrant RSUs have vested as of December 31, 2022. In addition, the Company granted 45,297 RSUs in 2020 and 4,431 earn-out RSUs and 88 Parent Warrant RSUs as part of the Merger in January 2021 to a non-executive officer that vest upon meeting certain revenue targets from the sale of specific products, of which 15,099 RSUs, 1,477 earn-out RSUs, and 30 Parent Warrant RSUs have vested as of December 31, 2022. These grants are also included in the above activity. As of December 31, 2022, there was unrecognized stock-based compensation related to unvested RSUs of $59.1 million, which is expected to be recognized over a weighted average period of 3.02 years. Warrants As of December 31, 2022, there were 462,335 Class A common stock warrants outstanding and exercisable issued to nonemployees in connection with vendor service arrangements, with a weighted average exercise price of $1.75, a weighted average contractual term of 7.01 years, and an aggregate intrinsic value of $2.2 million. Upon the exercise of outstanding warrants, vendors also have the right to receive 45,225 shares of Merger consideration, consisting of the holders’ allocation of earn-out consideration. As of December 31, 2022, all stock-based compensation expense related to vendor warrants and associated earn-out shares has been recognized. As of December 31, 2022, there were 98,723 Class A common stock warrants outstanding and exercisable issued in connection with a pre-Merger debt arrangement, with a weighted average exercise price of $6.96, a weighted average contractual term of 6.71 years, and no aggregate intrinsic value. These debt warrants were recorded in additional paid-in capital as a result of their conversion to equity-classified Class A common stock warrants in connection with the Merger. Acquisitions As part of the acquisitions of HHL and Apostrophe, the Company issued 177,327 and 5,742,378 shares of Class A common stock, respectively. In each acquisition, the Company also issued additional shares of Class A common stock that are subject to vesting. Stock Subject to Vesting and Earn-out Share Liability In June 2021, the Company granted 447,553 restricted shares of Class A common stock subject to vesting with an aggregate grant date fair value of $5.5 million in connection with the acquisition of HHL. As part of the acquisition of HHL, the Company also recognized an earn-out liability based on the achievement of certain revenue targets. A portion of the earn-out liability is expected to be settled in shares of Class A common stock. Vesting of the restricted shares and a portion of total earn-out payable to specific individuals are contingent on each recipient’s continued employment. Accordingly, the Company has recognized stock-based compensation expense related to these awards for the years ended December 31, 2022 and 2021. The expense will be recognized over a four-year vesting period with 25% vesting one year after the acquisition date and the remaining vesting quarterly thereafter. As of December 31, 2022, there was unrecognized stock-based compensation expense of $3.6 million, which will be recognized over a weighted average period of 2.36 years. In July 2021, the Company granted 2,332,557 restricted shares of Class A common stock subject to vesting with an aggregate grant date fair value of $24.2 million in connection with the acquisition of Apostrophe. Vesting of the restricted shares is contingent on each recipient’s continued employment. Accordingly, the Company has recognized stock-based compensation expense related to these awards for the years ended December 31, 2022 and 2021. The expense will be recognized over a three-year vesting period with 17% vesting 6 months after the acquisition date and the remaining vesting quarterly thereafter. As of December 31, 2022, there was unrecognized stock-based compensation expense of $12.1 million, which will be recognized over a weighted average period of 1.50 years. Stock-Based Compensation Expense The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022, 2021, and 2020 (in thousands): Year Ended December 31, 2022 2021 2020 Marketing $ 4,648 $ 9,664 $ 1,172 Operations and support 2,684 2,735 155 Technology and development 4,327 4,481 269 General and administrative 31,158 50,331 4,235 Total stock-based compensation expense $ 42,817 $ 67,211 $ 5,831 The Company capitalized $0.6 million and $0.7 million of stock-based compensation as internal-use software for the years ended December 31, 2022 and 2021, respectively, and none for the year ended December 31, 2020.

Related-Party Transactions

Related-Party Transactions	12 Months Ended
Related-Party Transactions	Dec. 31, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party TransactionsAtomic Labs, LLC (“Atomic Labs”) is a related-party venture capital startup studio that launched the Company, providing initial capital and governance. The Company utilized operational support from Atomic Labs, primarily consisting of providing office space, conducting back-office professional services, and administering operating expenses. Additionally, an affiliated company of Atomic Labs provides professional services to the Company, primarily to support engineering and operations functions. All services were provided at cost. For the years ended December 31, 2022, 2021, and 2020, the Company recorded a total of $3.6 million, $3.5 million, and $3.4 million, respectively, for payments made to an affiliated company of Atomic Labs for services performed and costs incurred on behalf of the Company. In addition, for the years ended December 31, 2022, 2021, and 2020, the Company recorded $1.0 million, $0.7 million, and $0.1 million, respectively, for payments made to Vouched, a related-party company that provides identity verification services.

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Share	12 Months Ended
Basic and Diluted Net Loss per Share	Dec. 31, 2022
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share Prior to the Merger and prior to effecting the recapitalization, the Company had two classes of common stock: Hims Class A and Hims Class F common stock. The rights of the holders of Hims Class A and Hims Class F common stock were identical, including the liquidation and dividend rights, except with respect to electing members of the Board of Directors and voting rights. As the liquidation and dividend rights were identical, undistributed earnings and losses were allocated on a proportionate basis and the resulting net loss per share attributable to common stockholders was the same for both Hims Class A and Hims Class F common stock on an individual and combined basis. Subsequent to the Merger, the Company continues to have two classes of common stock: Class A and Class V common stock. Similar to the previous structure, the rights are identical, including liquidation and dividend rights, except Class V common stock has additional voting rights. The Company uses the two-class method to calculate net loss per share. No dividends were declared or paid for the years ended December 31, 2022, 2021, and 2020. Undistributed earnings for each period are allocated to participating securities, including the redeemable convertible preferred stock, based on the contractual participation rights of the security to share in the current earnings as if all current period earnings had been distributed. As there is no contractual obligation for the redeemable convertible preferred stock to share in losses, the Company’s basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average shares of common stock outstanding during periods with undistributed losses. The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts): Year Ended December 31, 2022 2021 2020 Class A Class V Class A Class V Class A Class F Numerator: Net loss attributable to common stockholders $ (62,988) $ (2,690) $ (103,082) $ (4,577) $ (14,558) $ (3,556) Denominator: Weighted average shares outstanding, basic and diluted 196,138,497 8,377,623 178,840,009 7,941,528 28,412,457 6,941,352 Basic and diluted net loss per share $ (0.32) $ (0.32) $ (0.58) $ (0.58) $ (0.51) $ (0.51) Basic net loss per share is the same as diluted net loss per share attributable to common stockholders for the years ended December 31, 2022, 2021, and 2020, because the inclusion of potential shares of common stock would have been anti-dilutive for the periods presented. There were no redeemable shares during the years ended December 31, 2022 or 2021. During the year ended December 31, 2020, weighted average Hims Class A common shares presented excludes 165,133 shares subject to redemption. Redeemable shares do not absorb losses. The following table discloses weighted-average securities that were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive: Year Ended December 31, 2022 2021 2020 Stock options 20,470,391 16,345,661 11,509,177 RSUs 8,778,890 4,081,026 114,624 Common stock issued subject to vesting 2,027,852 1,419,613 — Common stock issuable under the ESPP 603,603 136,538 — Warrants to purchase Class A common stock 561,058 4,778,003 1,767,451 Common stock issued for early exercise of stock options 70,257 196,431 99,548 Redeemable convertible preferred stock — 4,858,176 90,268,364 Common stock issued for exercise of stock options subject to nonrecourse promissory notes — 874,312 16,514,103 Warrants to purchase redeemable convertible preferred stock — — 931,668

Income Tax

Income Tax	12 Months Ended
Income Tax	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax	Income Tax For financial reporting purposes, loss before income taxes includes the following (in thousands): Year Ended December 31, 2022 2021 2020 Domestic $ (62,539) $ (109,393) $ (16,934) Foreign (3,170) (1,402) (1,053) Loss before income taxes $ (65,709) $ (110,795) $ (17,987) The (benefit) provision for income taxes consisted of the following (in thousands): Year Ended December 31, 2022 2021 2020 Current: Federal $ — $ — $ — State 563 252 127 Foreign — — — Total current provision 563 252 127 Deferred: Federal (339) (2,280) — State (110) (966) — Foreign (145) (142) — Total deferred benefit (594) (3,388) — Total (benefit) provision for income taxes $ (31) $ (3,136) $ 127 The (benefit) provision for income taxes differs from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as follows (in thousands): Year Ended December 31, 2022 2021 2020 Tax benefit at federal statutory rate $ (13,799) $ (23,267) $ (3,777) State taxes, net of federal benefits (609) (3,498) (364) Transaction costs (731) 369 — Stock-based compensation 3,897 2,018 698 Warrants and earn-outs (15) (1,710) (403) Non-deductible officers' compensation 2,881 8,352 — Change in valuation allowance 7,794 15,971 3,948 Other, net 551 (1,371) 25 Total $ (31) $ (3,136) $ 127 The components of deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 67,214 $ 61,640 Accrued expenses and reserves 1,952 1,245 Stock-based compensation 4,079 4,130 Inventory 2,338 2,214 Other intangibles 487 49 Deferred revenue 17 — Operating lease liabilities 1,382 1,441 Other deferred tax assets 553 456 Total gross deferred tax assets 78,022 71,175 Less valuation allowance (69,357) (61,328) Total deferred tax assets 8,665 9,847 Deferred tax liabilities: Other intangibles (5,623) (6,933) Fixed assets (1,722) (2,088) Operating lease right-of-use assets (1,285) (1,343) Other deferred tax liabilities (70) (112) Total deferred tax liabilities (8,700) (10,476) Net deferred tax liabilities $ (35) $ (629) The Company determines its valuation allowance on deferred tax assets by considering both positive and negative evidence to ascertain whether it is more likely than not that deferred tax assets will be realized. Realization of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain. Due to the Company's history of losses, the Company believes that it is not more likely than not that all of the deferred tax assets can be realized as of December 31, 2022 and 2021. Accordingly, the Company has recorded a valuation allowance against its deferred tax assets. The net deferred tax liability is primarily the result of acquired intangibles for which there is no tax basis. The valuation allowance increased by $8.0 million and $16.8 million during the years ended December 31, 2022 and 2021, respectively. During 2021, the Company recorded a one-time benefit of approximately $3.1 million due to the release of the valuation allowance as a result of the Apostrophe acquisition. As of December 31, 2022, the Company has $245.6 million, $204.2 million, and $5.9 million in federal, state, and foreign loss carryforwards (not tax effected), respectively, of which $238.8 million, $19.8 million, and $5.9 million in federal, state, and foreign loss carryforwards do not expire. The remaining federal and state loss carryforwards begin to expire in 2036 and 2023, respectively. Internal Revenue Code Sections 382 and 383 place a limitation on the amount of taxable income that can be offset by carryforward tax attributes, such as net operating losses or tax credits, after a change in control. Generally, after a change in control, a loss corporation cannot deduct carryforward tax attributes in excess of the limitation prescribed by Sections 382 and 383. Therefore, certain of the Company’s carryforward tax attributes may be subject to an annual limitation regarding their utilization against taxable income in future periods. As a result of issuances of different classes of preferred stock to investors in 2017, 2018, and 2019, the Company triggered “ownership change(s)” as defined in Section 382 and related provisions. The Company believes that some of its net operating losses may be limited by these ownership changes but that any limitation would not have a significant impact to the financial statements since there is no utilization of the net operating losses and a valuation allowance exists against the net operating losses. Subsequent ownership changes may subject the Company to annual limitations of its net operating losses. Such annual limitation could result in the expiration of the net operating loss and credit carryforwards before utilization. Use of certain losses incurred within the U.K. are also limited, but any limitation would not have a significant impact to the financial statements since a valuation allowance exists against the net operating losses. The Company has incurred net operating losses since inception, and it does not have any significant unrecognized tax benefits. Any adjustments to the Company’s uncertain tax positions would result in an adjustment of its net operating loss and valuation allowance rather than resulting in an impact to the effective tax rate. It is not expected that there will be any material change in the unrecognized tax benefits within the next 12 months. The Company files income tax returns in the U.S., U.K., and various state and local jurisdictions. Due to the net operating loss carryforward, the statute of limitations is open for 2017 and forward for all jurisdictions, none of which are currently under examination by any tax authorities. On August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law. The new legislation imposes a 15% minimum tax on certain corporation’s book income and a 1% excise tax on certain stock buybacks. While the Company may be subject to the new excise tax on certain stock buybacks in the future, the enactment of the IRA did not result in any material adjustments to the consolidated financial statements for the year ended December 31, 2022

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	The accompanying consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities for which it is the primary beneficiary. All intercompany transactions and balances have been eliminated in the consolidated financial statements herein.
Reclassifications	Beginning with the year ended December 31, 2022, the Company voluntarily reclassified certain operating expenses within the consolidated statements of operations and comprehensive loss. Prior period amounts have been reclassified to conform to this presentation. These changes have no impact on the Company’s previously reported financial position or results of operations. These classification changes are related to breaking out the Company’s previous selling, general, and administrative caption into three new captions entitled: (i) operations and support, (ii) technology and development, and (iii) general and administrative. The operations and support caption includes costs related to the Company’s supply chain, fulfillment and customer support functions. The technology and development caption includes costs related to the operation and enhancement of the Company’s digital platform and product development. The general and administrative caption includes costs relating to the Company’s corporate functions, including personnel costs, professional services, insurance, depreciation and amortization relating to corporate operating activities, and other general corporate costs.
Use of Estimates	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates, judgements, and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation of contingent consideration in business combinations, purchase price allocation for business combinations, estimates used in the capitalization of website and mobile application development and internal-use software costs, and judgements relating to impairment triggering events for long-lived assets. Management believes that the estimates, judgments, and assumptions upon which it relies are reasonable based upon information available to it at the time that these estimates, judgments, and assumptions were made. Actual results experienced by the Company may differ from management’s estimates. To the extent that there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected.
Risks and Uncertainties	The Company’s business, operations, and financial results are subject to various risks and uncertainties, including adverse United States economic conditions, legal restrictions, changing laws for medical services and prescription products, decisions to outsource or modify portions of its supply chain, and competition in its industry, and of which could adversely affect its business, financial condition, results of operations, and cash flows. These significant factors, among others, could cause the Company’s future results to differ materially from the consolidated financial statements.
Concentration Risk	The Company’s financial instruments that are potentially exposed to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, investments, and accounts receivable. The Company maintains its cash, cash equivalents, short-term investments, and restricted cash with high-quality financial institutions with investment-grade ratings. The majority of the cash balances are with U.S. banks and are insured to the extent defined by the Federal Deposit Insurance Corporation.
Foreign Currency Translation	The Company’s consolidated financial statements are presented in U.S. dollars. Adjustments resulting from translating foreign functional currency financial statements into U.S. dollars are presented as foreign currency translation adjustments, a component of other comprehensive loss on the consolidated statements of operations and comprehensive loss.
Business Combinations	The Company accounts for its business combinations using the acquisition method of accounting. The purchase price is attributed to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of acquisition. When the Company issues stock-based or cash awards to an acquired company’s shareholders, the Company evaluates whether the awards are consideration or compensation for post-acquisition services. The evaluation includes, among other things, whether the vesting of the awards is contingent on the continued employment of the acquired company’s stockholders beyond the acquisition date. If continued employment is required for vesting, the awards are treated as compensation for post-acquisition services and recognized as expense over the requisite service period. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain assumed obligations. Any acquired assets from a business combination including intangible assets subject to amortization are continuously monitored and reviewed for potential impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets.
Segment Reporting	The Company is managed as a single operating segment on a consolidated basis, inclusive of acquisitions. The Company determined that the Chief Executive Officer (“CEO”) is the chief operating decision maker as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions and managing the organization at a consolidated level.
Cash, Cash Equivalents, and Restricted Cash	The Company considers all highly liquid investments purchased with an original maturity or remaining maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash and cash equivalents with financial institutions. The restricted cash balance comprises cash collateral that is held by the Company’s primary financial institution to secure a letter of credit issued as a security deposit for the Company’s warehouse facility in New Albany, Ohio.
Investments	Available-for-sale debt instruments with original maturities at the date of purchase greater than three months and remaining maturities of less than one year are classified as short-term investments. Available-for-sale debt instruments with original maturities at the date of purchase and remaining maturities of greater than one year are classified as long-term investments. The Company intends to sell such investments, if any, at or close to maturity. The investments are designated as available-for-sale and are reported at fair value, with unrealized gains and losses, net of tax, recorded in other comprehensive loss on the consolidated statements of operations and comprehensive loss, except for other-than-temporary impairments and credit losses. The Company determines the cost of the investment sold based on specific identification at the individual security level. The Company records the interest income and realized gains and losses on the sale of these instruments within other income (expense), net on the consolidated statements of operations and comprehensive loss.
Other-Than-Temporary Impairment and Credit Losses	Prior to 2021, the Company followed the guidance in Accounting Standards Codification (“ASC”) Topic 320, Investments – Debt and Equity Securities in determining whether unrealized losses were other than temporary. The Company adopted ASC Topic 326 for the year ended December 31, 2021, and now considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company’s available-for-sale securities for the years ended December 31, 2022, 2021, or 2020 were caused by fluctuations in market value and interest rates as a result of the economic environment. The Company concluded that an allowance for credit losses was unnecessary as of December 31, 2022 and 2021 and that there were no impairments as of December 31, 2020 considered as other-than-temporary because the decline in the market value was attributable to changes in market conditions and not credit quality, and that it is neither management’s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value. There was no realized gain or loss on available-for-sale securities in the periods presented.
Fair Value of Financial Instruments	The fair value of a financial instrument is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities subject to ongoing fair value measurement are categorized and disclosed into one of the three categories depending on observable or unobservable inputs employed in the measurement. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. • Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Inventory	Inventory primarily consists of finished goods and raw materials that are located at Company-managed and third-party fulfillment warehouses and pharmacies. Inventory is stated at the lower of cost and net realizable value and inventory cost is determined by the weighted average cost method. The Company reserves for expired, slow-moving, and excess inventory by estimating the net realizable value based on the potential future use of such inventory. Management monitors inventory to identify events that would require impairment due to slow-moving, expired, or obsolete inventory and reduces the value of inventory when required. Obsolete inventory balances are written off against the inventory allowance when management determines that the inventory cannot be sold.
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of balances related to prepayments or vendor deposits for insurance, marketing, software, inventory and other operating costs, and trade and other accounts receivables. Prepaid expenses are recorded when payment has been made in advance for goods and services. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Receivables are stated at amounts estimated by management to be equal to their net realizable values. The allowance for doubtful accounts is the Company's best estimate of the amount of expected credit losses. The expectation of collectability is based on the Company's review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and an allowance is recorded accordingly. Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
Other Long-Term Assets	Property and equipment are recorded at cost, less accumulated depreciation and amortization. Maintenance and repair costs are charged to expense as incurred, and expenditures that extend the useful lives of assets are capitalized. Property and equipment are depreciated or amortized using the straight-line method over the estimated useful lives ranging from two
Goodwill	Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually in the fourth quarter or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company operates as one reporting unit. When testing goodwill for impairment, the Company may first perform an optional qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company will recognize an impairment loss in an amount equal to that excess but limited to the total amount of goodwill.
Intangible Assets	Intangible assets primarily includes trade name, customer relationships, and developed technology. The Company amortizes such definite-lived intangible assets on a straight-line basis over the assets’ estimated useful lives of two
Impairment of Long-Lived Assets	Long-lived assets include property and equipment, website and mobile application development and internal-use software, and intangible assets subject to amortization. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. As of December 31, 2021 and 2020, the Company determined that no events or changes in circumstances existed that would indicate any impairment of its long-lived assets. The Company recognized $1.1 million of impairment charges on long-lived assets during the year ended December 31, 2022 in general and administrative expenses on the consolidated statements of operations and comprehensive loss.
Operating Leases	The Company determines if an arrangement contains a lease at inception based on whether there is identified property, plant, or equipment and whether the Company controls the use of the identified asset throughout the period of use. The Company leases two real estate facilities under non-cancelable operating leases with expiration dates in fiscal years 2025 and 2027. The Company's operating leases are reflected in the operating lease right-of-use (“ROU”) assets and in the operating lease liabilities in the accompanying consolidated balance sheets. The operating lease ROU assets represent the Company’s right to use the underlying assets for the lease terms and the lease liabilities represent the Company’s obligation to make lease payments arising from the leases. The operating lease ROU assets and lease liabilities are recognized at each lease’s inception date based on the present value of lease payments over the lease term discounted based on the more readily determinable of (i) the rate implicit in the lease or (ii) the Company’s incremental borrowing rate, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease. Because the Company’s operating leases do not provide an implicit rate, the Company estimates its incremental borrowing rate at the lease commencement date for borrowings with a similar term. The Company’s operating lease ROU assets are measured based on the corresponding operating lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. The Company does not assume renewals or early terminations unless it is reasonably certain to exercise these options at commencement. The Company does not allocate consideration between lease and non-lease components. The Company's lease agreements contain variable costs such as common area maintenance, operating expenses, or other costs. Variable lease payments are recognized in the period in which the obligation for those payments are incurred. In addition, the Company does not recognize ROU assets or operating lease liabilities for leases with a term of 12 months or less of all asset classes. Operating lease expense is recognized on a straight-line basis over each lease term.
Revenue Recognition	The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. The Company’s consolidated revenue primarily comprises online sales of health and wellness products and services through the Company’s websites and mobile applications, including prescription and non-prescription products. In contracts that contain prescription products issued as the result of a consultation, revenue also includes medical consultation services provided by Affiliated Medical Groups (defined below). Additionally, the Company offers a range of health and wellness products through wholesale partners. For Online Revenue, the Company defines its customer as an individual who purchases products or services through its websites or mobile applications. For Wholesale Revenue, the Company defines its customer as a wholesale partner, with the exception of consignment arrangements, where its customer is defined as an individual who purchases products through certain third-party platforms. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills and contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically within one day. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus estimates. For each of the years ended December 31, 2022, 2021, and 2020, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups,” which are professional corporations or other professional entities owned by licensed physicians and that engage licensed healthcare professionals (physicians, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 11 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, in its sole discretion, sets all listed prices charged on its websites and mobile applications for products and services. Additionally, to fulfill its promise to customers for contracts that include sale of prescription products, the Company maintains relationships with (i) certain third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) and (ii) XeCare, LLC (“XeCare”) and Apostrophe Pharmacy LLC (“Apostrophe Pharmacy”, and together with XeCare, the “Affiliated Pharmacies”), which are licensed mail order pharmacies providing prescription fulfillment solely to the Company’s customers. The Partner Pharmacies and the Affiliated Pharmacies fill prescription orders for customers who have received a prescription from a prescribing Provider through the Company’s websites and mobile applications. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy or Affiliated Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies and Affiliated Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, in its sole discretion, sets all listed prices charged on its websites and mobile applications for products and services. The Company estimates refunds using the expected value method primarily based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. For online sales, payment for prescription medication and non-prescription products is typically collected from the customer a few days in advance of product shipment. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the consolidated balance sheets since the associated revenue will be primarily recognized within the following month. For wholesale arrangements, payments are collected in accordance with contract terms.
Cost of Revenue	Cost of revenue consists of costs directly attributable to the products shipped and services rendered, including product costs, packaging materials, shipping costs, and labor costs directly related to revenue generating activities. Costs related to free products where there is no expectation of future purchases from a customer and depreciation and amortization on property and equipment are considered to be operating expenses and are excluded from cost of revenue.
Stock-based Compensation	The fair value of stock options, equity-classified warrants issued to vendors, and restricted stock units (“RSUs”), are measured at the grant date fair value. The fair value of employee stock options and vendor warrants are generally determined using the Black-Scholes Merton (“BSM”) option-pricing model using various inputs, including estimates of expected volatility, term, risk-free rate, and future dividends. Stock options that were granted to the Company’s CEO with performance and market conditions and earn-out RSUs were valued using the Monte Carlo simulation model. The Company recognizes compensation costs on a straight-line basis over the requisite service period of the employee and vendor, which is generally the vesting term of four years for options, warrants, and RSUs that do not have performance or market conditions. Stock options and RSUs with performance conditions are recognized when it is probable that performance criteria will be achieved and compensation cost is recognized using the accelerated attribution method. The Company accounts for forfeitures as they occur. The Company’s Employee Stock Purchase Plan (“ESPP”) permits eligible employees to purchase the Company’s Class A common stock during pre-specified offering periods at a discount established by the compensation committee. The purchase price is 85% of the lower of the fair market value of the Company’s Class A common stock on the first trading day of the offering period and the fair market value on the purchase date. The ability to purchase shares of the Company’s Class A common stock for a discount represents an option and, therefore, the ESPP is considered a compensatory plan. Accordingly, stock-based compensation expense is determined based on the option’s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the requisite service period, which is the withholding period.
Income Taxes	The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax reporting basis of assets and liabilities. These differences are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company recognizes the effect on deferred income taxes of a change in tax rates in the period that includes the enactment date. The Company provides a valuation allowance, if necessary, to reduce its deferred tax assets to the net amount it believes is more likely than not to be realized. The Company considers both positive and negative evidence, including its historical operating results, forecasts of future taxable income on a jurisdiction-by-jurisdiction basis, and ongoing tax planning strategies, to ascertain the need for a valuation allowance. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes.
Employee Benefit Plan	The Company has established a 401(k) plan that qualifies as a deferred compensation arrangement under Section 401 of the Internal Revenue Code. Beginning in 2021, the Company contributes 50% of eligible employee’s elective deferrals up to an annual maximum of three thousand dollars per employee. The Company recognized matching contributions cost of $1.2 million and $0.7 million for the years ended December 31, 2022 and 2021, respectively.
Advertising	For the years ended December 31, 2022, 2021, and 2020, advertising costs for customer acquisition and content production were $235.6 million, $103.5 million, and $45.2 million, respectively. Customer acquisition expenses are charged to expense as incurred and recorded within marketing expense on the consolidated statements of operations and comprehensive loss. The Company defers production costs associated with advertising campaigns until the date of first showing.
Other Comprehensive Income	The Company’s other comprehensive loss is impacted by foreign currency translation and available-for-sale investment fair value adjustments. The impact of foreign currency translation is affected by the translation of assets and liabilities of the Company’s United Kingdom foreign subsidiary, which is denominated in pounds sterling. The primary assets and liabilities affecting the adjustments are cash and cash equivalents, other assets, accounts payable and accrued liabilities, and long-term liabilities. The impact of available-for-sale securities is primarily affected by unrecognized gains and losses related to fluctuations in the fair market value of the securities
Liquidity	The Company’s operations have been financed primarily through the issuance of common and preferred stock. Since inception, the Company has incurred negative cash flows as it is expending significant resources in expanding its activities. This has resulted in losses from operations, which are expected to continue for at least the next 12 months, and an accumulated deficit. The Company may require additional financing to fund operations to meet its business plan.The Company believes that its existing cash and investment balances are sufficient for the Company to meet its obligations through at least one year from the date of issuance of the consolidated financial statements. Management considers that there are no conditions or events in the aggregate that raise substantial doubt about the entity’s ability to continue as a going concern for a period of at least one year from the date the consolidated financial statements are issued.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company does not expect that any recently issued accounting pronouncements will have a material effect on its financial statements.
Fair Value Measurements	The fair value measurements of the identified intangible assets were based primarily on significant unobservable inputs and thus represent a Level 3 measurement as defined in ASC 820. The fair values of trade name and developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets including revenue and cash flow forecasts, customer churn rate, technology life, royalty rate, and discount rate. The fair value of customer relationships was determined using the multi-period excess earnings method which involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets, and then discounting the resulting net cash flows to a present value using an appropriate discount rate.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Capitalized Computer Software, Expected Amortization	The following table summarizes the estimated amortization of website development and internal-use software costs subsequent to December 31, 2022 (in thousands): 2023 $ 3,760 2024 2,892 2025 1,528 Total $ 8,180
Disaggregation of Revenue	Revenue consists of the following (in thousands): Year Ended December 31, 2022 2021 2020 Online Revenue $ 502,507 $ 259,170 $ 140,728 Wholesale Revenue 24,409 12,708 8,029 Total revenue $ 526,916 $ 271,878 $ 148,757

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
Acquisitions (Tables)	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 1,470 Other intangible assets 570 Goodwill 2,739 Other net assets 24 Net assets acquired $ 4,803 The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 22,700 Other intangible assets 3,140 Goodwill 108,142 Other net liabilities (2,346) Net assets acquired $ 131,636

Investments (Tables)

Investments (Tables)	12 Months Ended
Investments (Tables)	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of short term investments	Short-term investments as of December 31, 2022, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair Corporate bonds $ 99,672 $ — $ (106) $ 99,566 Government and government agency 33,317 17 (47) 33,287 Total short-term investments $ 132,989 $ 17 $ (153) $ 132,853 Short-term investments as of December 31, 2021, consist of the following (in thousands): Adjusted Unrealized Fair Corporate bonds $ 146,032 $ (30) $ 146,002 Asset-backed bonds 29,507 (19) 29,488 Total short-term investments $ 175,539 $ (49) $ 175,490

Inventory (Tables)

Inventory (Tables)	12 Months Ended
Inventory (Tables)	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventory consists of the following (in thousands): December 31, 2022 2021 Finished goods $ 16,477 $ 10,428 Raw materials 5,085 3,130 Total inventory $ 21,562 $ 13,558

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2022 2021 Wholesale trade receivables $ 3,231 $ 3,577 Prepaid expenses 10,392 4,606 Other current assets 1,785 890 Total prepaid expenses and other current assets $ 15,408 $ 9,073

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
Intangible Assets (Tables)	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets as of December 31, 2022 consist of the following (in thousands): Gross Accumulated Amortization and Impairment Net Weighted Trade name $ 24,170 $ (4,504) $ 19,666 8.4 Other 4,581 (2,406) 2,175 4.7 Intangible assets, net $ 28,751 $ (6,910) $ 21,841 8.0 Intangible assets as of December 31, 2021 consist of the following (in thousands): Gross Accumulated Net Weighted Trade name $ 24,170 $ (1,298) $ 22,872 9.2 Other 3,846 (828) 3,018 2.4 Intangible assets, net $ 28,016 $ (2,126) $ 25,890 8.4
Finite-lived Intangible Assets Amortization Expense	Amortization that will be charged to expense over the remaining life of the intangible assets subsequent to December 31, 2022 is as follows (in thousands): 2023 $ 3,434 2024 2,694 2025 2,560 2026 2,452 2027 and thereafter 10,701 $ 21,841

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
Accrued Liabilities (Tables)	Dec. 31, 2022
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): December 31, 2022 2021 Payroll $ 4,999 $ 3,363 Marketing 4,990 3,158 Tax 963 954 Professional services 643 734 Product and shipping 263 2,635 Other accruals 590 1,350 Total accrued liabilities $ 12,448 $ 12,194

Operating Leases (Tables)

Operating Leases (Tables)	12 Months Ended
Operating Leases (Tables)	Dec. 31, 2022
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity	Future minimum lease payments under the Company's non-cancelable operating lease with an initial lease term in excess of one year subsequent to December 31, 2022 are as follows (in thousands): 2023 $ 1,876 2024 1,924 2025 1,408 2026 303 2027 259 Gross lease payments 5,770 Less: imputed interest (463) Present value of net future minimum lease payments $ 5,307

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 24,606 $ — $ — $ 24,606 Government bonds — 11,315 — 11,315 Short-term investments: Corporate bonds — 99,566 — 99,566 Government and government agency — 33,287 — 33,287 Restricted cash: Money market funds 856 — — 856 Total assets $ 25,462 $ 144,168 $ — $ 169,630 Liabilities Earn-out liabilities $ — $ — $ 2,975 $ 2,975 Total liabilities $ — $ — $ 2,975 $ 2,975 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 59,761 $ — $ — $ 59,761 Government bonds — 7,664 — 7,664 Short-term investments: Corporate bonds — 146,002 — 146,002 Government bonds — 29,488 — 29,488 Restricted cash: Money market funds 856 — — 856 Total assets $ 60,617 $ 183,154 $ — $ 243,771 Liabilities Earn-out liabilities $ — $ — $ 1,999 $ 1,999 Total liabilities $ — $ — $ 1,999 $ 1,999
Fair Value Measurement Inputs and Valuation Techniques	The following assumptions were used to determine the fair value at inception: HHL Revenue risk-adjusted discount rate 9.1 % Revenue volatility 50.0 % Counterparty discount rate 5.0 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The change in the fair value of earn-out liabilities is as follows (in thousands): Balance at December 31, 2020 $ — HHL acquisition 1,208 Apostrophe acquisition 32,650 Change in fair value due to revaluation and service-based vesting 10,975 Reclassification to earn-out payable (42,834) Balance at December 31, 2021 1,999 Change in fair value due to revaluation and service-based vesting 976 Balance at December 31, 2022 $ 2,975

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The grant date fair value of the Company’s stock options granted (excluding the stock options granted to the CEO outlined above) was estimated using the following weighted average assumptions: Year Ended December 31, 2022 2021 2020 Expected term (in years) 6.02 5.94 5.94 Expected volatility 48.0 % 58.6 % 62.3 % Risk-free interest rate 2.0 % 0.9 % 0.5 % Expected dividend yield — % — % — %
Share-based Payment Arrangement, Option, Activity	Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2021 10,401 $ 4.01 7.73 $ 37,868 Granted 6,321 5.10 Exercised (including early exercised options vested during the period) (1,728) 1.42 Forfeited and expired (544) 6.97 Outstanding at December 31, 2022 14,450 4.68 7.98 35,771 Exercisable as of December 31, 2022 8,389 3.81 7.16 28,509
Share-based Payment Arrangement, Option, Exercise Price Range	The options outstanding and exercisable as of December 31, 2022 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Shares Weighted $0.06 – 0.40 1,830 5.21 1,830 5.21 1.55 – 1.75 959 6.43 959 6.43 2.43 – 3.11 3,037 7.50 2,921 7.42 5.01 – 6.82 6,190 9.21 977 9.17 8.13 – 9.41 1,569 8.13 1,301 8.04 12.21 – 15.17 865 8.19 401 8.03 14,450 8,389 The options outstanding and exercisable as of December 31, 2021 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Shares Weighted $0.06 – 0.40 2,309 5.64 2,308 5.64 1.55 – 1.75 2,120 7.34 2,006 7.34 2.43 3,242 8.42 3,241 8.42 8.13 – 9.41 1,756 8.82 1,291 8.54 12.21 – 15.17 974 9.28 128 9.02 10,401 8,974
Share-based Payment Arrangement, Restricted Stock Unit, Activity	RSU activity is as follows (in thousands, except for weighted average grant date fair value): Shares Weighted Average Unvested at December 31, 2021 3,982 $ 11.55 Granted 10,536 4.97 Vested (2,294) 8.86 Forfeited and expired (623) 8.05 Unvested at December 31, 2022 11,601 $ 6.40
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022, 2021, and 2020 (in thousands): Year Ended December 31, 2022 2021 2020 Marketing $ 4,648 $ 9,664 $ 1,172 Operations and support 2,684 2,735 155 Technology and development 4,327 4,481 269 General and administrative 31,158 50,331 4,235 Total stock-based compensation expense $ 42,817 $ 67,211 $ 5,831

Basic and Diluted Net Loss pe_2

Basic and Diluted Net Loss per Share (Tables)	12 Months Ended
Basic and Diluted Net Loss per Share (Tables)	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts): Year Ended December 31, 2022 2021 2020 Class A Class V Class A Class V Class A Class F Numerator: Net loss attributable to common stockholders $ (62,988) $ (2,690) $ (103,082) $ (4,577) $ (14,558) $ (3,556) Denominator: Weighted average shares outstanding, basic and diluted 196,138,497 8,377,623 178,840,009 7,941,528 28,412,457 6,941,352 Basic and diluted net loss per share $ (0.32) $ (0.32) $ (0.58) $ (0.58) $ (0.51) $ (0.51)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table discloses weighted-average securities that were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive: Year Ended December 31, 2022 2021 2020 Stock options 20,470,391 16,345,661 11,509,177 RSUs 8,778,890 4,081,026 114,624 Common stock issued subject to vesting 2,027,852 1,419,613 — Common stock issuable under the ESPP 603,603 136,538 — Warrants to purchase Class A common stock 561,058 4,778,003 1,767,451 Common stock issued for early exercise of stock options 70,257 196,431 99,548 Redeemable convertible preferred stock — 4,858,176 90,268,364 Common stock issued for exercise of stock options subject to nonrecourse promissory notes — 874,312 16,514,103 Warrants to purchase redeemable convertible preferred stock — — 931,668

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
Income Tax (Tables)	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	For financial reporting purposes, loss before income taxes includes the following (in thousands): Year Ended December 31, 2022 2021 2020 Domestic $ (62,539) $ (109,393) $ (16,934) Foreign (3,170) (1,402) (1,053) Loss before income taxes $ (65,709) $ (110,795) $ (17,987)
Schedule of Components of Income Tax Expense (Benefit)	The (benefit) provision for income taxes consisted of the following (in thousands): Year Ended December 31, 2022 2021 2020 Current: Federal $ — $ — $ — State 563 252 127 Foreign — — — Total current provision 563 252 127 Deferred: Federal (339) (2,280) — State (110) (966) — Foreign (145) (142) — Total deferred benefit (594) (3,388) — Total (benefit) provision for income taxes $ (31) $ (3,136) $ 127
Schedule of Effective Income Tax Rate Reconciliation	The (benefit) provision for income taxes differs from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as follows (in thousands): Year Ended December 31, 2022 2021 2020 Tax benefit at federal statutory rate $ (13,799) $ (23,267) $ (3,777) State taxes, net of federal benefits (609) (3,498) (364) Transaction costs (731) 369 — Stock-based compensation 3,897 2,018 698 Warrants and earn-outs (15) (1,710) (403) Non-deductible officers' compensation 2,881 8,352 — Change in valuation allowance 7,794 15,971 3,948 Other, net 551 (1,371) 25 Total $ (31) $ (3,136) $ 127
Schedule of Deferred Tax Assets and Liabilities	The components of deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 67,214 $ 61,640 Accrued expenses and reserves 1,952 1,245 Stock-based compensation 4,079 4,130 Inventory 2,338 2,214 Other intangibles 487 49 Deferred revenue 17 — Operating lease liabilities 1,382 1,441 Other deferred tax assets 553 456 Total gross deferred tax assets 78,022 71,175 Less valuation allowance (69,357) (61,328) Total deferred tax assets 8,665 9,847 Deferred tax liabilities: Other intangibles (5,623) (6,933) Fixed assets (1,722) (2,088) Operating lease right-of-use assets (1,285) (1,343) Other deferred tax liabilities (70) (112) Total deferred tax liabilities (8,700) (10,476) Net deferred tax liabilities $ (35) $ (629)

Organization (Details)

Organization (Details)	Jan. 20, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recapitalization exchange ratio	0.4530

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Accounts receivable	$ 3,900,000	$ 4,100,000
Accounts receivable, writeoff	0	0	$ 0
Accounts receivable, allowance for doubtful accounts	$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Other Long-Term Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 3	$ 2.2
Website development and internal-use software costs	$ 8.2	$ 5.7
Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	2 years
Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Amortization of Website Development and Internal-use Software Costs (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Accounting Policies [Abstract]
2023	$ 3,760
2024	2,892
2025	1,528
Total	$ 8,180

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Goodwill (Details)	6 Months Ended	12 Months Ended
	Sep. 30, 2021 USD ($)	Dec. 31, 2022 USD ($) reportingUnit	Dec. 31, 2021 USD ($)
Accounting Policies [Abstract]
Number of reporting units \| reportingUnit		1
Goodwill, acquired during period	$ 110,900,000
Goodwill, impairment		$ 0	$ 0

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2022
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	2 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	10 years

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Impairment of Long Lived Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Impairment of long-lived assets	$ 1,127,000	$ 0	$ 0

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 526,916	$ 271,878	$ 148,757
Online Revenue
Disaggregation of Revenue [Line Items]
Total revenue	502,507	259,170	140,728
Wholesale Revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 24,409	$ 12,708	$ 8,029

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Stock-Based Compensation (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		4 years
Common stock issuable under the ESPP \| Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock, percent	85%	85%

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Employee Benefit Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Percent of match	50%
Maximum annual contributions per employee, amount	$ 3,000
Matching contribution cost	$ 1,200,000	$ 700,000

Summary of Significant Accou_13

Summary of Significant Accounting Policies - Advertising (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Customer acquisition costs	$ 235.6	$ 103.5	$ 45.2

Summary of Significant Accou_14

Summary of Significant Accounting Policies - Liquidity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Net income (loss)	$ (65,678)	$ (107,659)	$ (18,114)
Net cash used in operating activities	(26,531)	(34,412)	(2,479)
Accumulated deficit	(344,629)	(278,951)
Cash and cash equivalents	46,772	71,784	$ 27,344
Short-term investments	$ 132,853	$ 175,490

Recapitalization (Details)

Recapitalization (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Jan. 20, 2021 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($)	Jan. 19, 2021 $ / shares
Reverse Recapitalization [Line Items]
Reverse recapitalization, percentage of voting interests acquired	100%
Proceeds from issuance of common stock upon Merger \| $	$ 197,700	$ 0	$ 197,686	$ 0
Reverse recapitalization, deferred transaction costs \| $	$ 18,700
Recapitalization exchange ratio	0.4530
Reverse recapitalization, contingent consideration, equity (in shares) \| shares	16,000,000
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share)	$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share)	17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share)	$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days	10 days
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading day period	20 days
Reverse recapitalization, contingent consideration, equity, earnout period	5 years
Chief Executive Officer
Reverse Recapitalization [Line Items]
Recapitalization exchange ratio	0.4530
Common Class A
Reverse Recapitalization [Line Items]
Class of warrant or right, number of securities called by each warrant or right (in shares) \| shares		0.0028
Parent Warrant Restricted Stock Units \| Hims' Option And RSU Holders
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) \| shares	35,000
Common Class A and V
Reverse Recapitalization [Line Items]
Recapitalization, contingent consideration, equity, exchange ratio	0.0443
Common Class A
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001	$ 0.0001
Common Class A \| Chief Executive Officer
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001
Common Class A \| Hims, Inc.
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)					$ 0.000001
Common Class A \| Parent Warrants \| Hims' Stockholders
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) \| shares	888,143
Common Class A \| Parent Warrants \| Hims' Warrant Holders
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) \| shares	3,443
Common Class V
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001
Common Class V \| Chief Executive Officer
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001
Common Class V \| Hims, Inc.
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)					$ 0.000001
PIPE Investment
Reverse Recapitalization [Line Items]
Sale of stock, number of shares issued in transaction (in shares) \| shares	7,500,000
Sale of stock, price per share (in dollars per share)	$ 10
Sale of stock, consideration received on transaction \| $	$ 75,000

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details)		1 Months Ended		6 Months Ended	12 Months Ended
Acquisitions - Narrative (Details)	Jun. 30, 2021 USD ($)	Jul. 31, 2021 USD ($) shares	Jun. 30, 2021 USD ($) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) acquisition	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Number of acquisitions \| acquisition					2
Goodwill				$ 110,881,000	$ 110,881,000		$ 110,881,000
Honest Health Limited
Business Acquisition [Line Items]
Business combination, consideration			$ 4,800,000
Business acquisition, equity interest issued or issuable, number of shares (in shares) \| shares			624,880
Business combination, consideration transferred, equity interests issued and issuable			$ 1,900,000
Business combination, consideration transferred, liabilities incurred			1,200,000
Potential earnout payable	$ 10,000,000		10,000,000
Business combination, acquisition related costs	1,900,000
Business combination, post-acquisition employee expense	700,000		700,000
Goodwill	2,739,000		2,739,000
Business acquisition, goodwill, expected tax deductible amount	$ 0		$ 0
Apostrophe
Business Acquisition [Line Items]
Business combination, consideration		$ 131,600,000
Business acquisition, equity interest issued or issuable, number of shares (in shares) \| shares		8,074,935
Business combination, consideration transferred, equity interests issued and issuable		$ 50,700,000
Business combination, consideration transferred, liabilities incurred		32,700,000
Potential earnout payable		50,000,000
Business combination, acquisition related costs		5,000,000
Business combination, post-acquisition employee expense		500,000
Goodwill		108,142,000
Business acquisition, goodwill, expected tax deductible amount		0
Cash consideration		$ 48,200,000
Business combination, pro forma information, revenue of acquiree since acquisition date, actual				$ 11,000,000
Business acquisition, pro forma revenue					$ 21,000,000	$ 13,000,000

Acquisitions - Assets Acquired

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Jul. 31, 2021	Jun. 30, 2021
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Goodwill	$ 110,881	$ 110,881
Honest Health Limited
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Trade name				$ 1,470
Other intangible assets				570
Goodwill				2,739
Other net assets (liabilities)				24
Net assets acquired				$ 4,803
Apostrophe
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Trade name			$ 22,700
Other intangible assets			3,140
Goodwill			108,142
Other net assets (liabilities)			(2,346)
Net assets acquired			$ 131,636

Investments (Details)

Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Adjusted Cost	$ 132,989	$ 175,539
Unrealized Gains	17
Unrealized Losses	(153)	(49)
Fair Value	132,853	175,490
Corporate bonds
Marketable Securities [Line Items]
Adjusted Cost	99,672	146,032
Unrealized Gains	0
Unrealized Losses	(106)	(30)
Fair Value	99,566	146,002
Asset-Backed Securities [Member]
Marketable Securities [Line Items]
Adjusted Cost	33,317	29,507
Unrealized Gains	17
Unrealized Losses	(47)	(19)
Fair Value	$ 33,287	$ 29,488

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 16,477	$ 10,428
Raw materials	5,085	3,130
Total inventory	$ 21,562	$ 13,558

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Wholesale trade receivables	$ 3,231	$ 3,577
Prepaid expenses	10,392	4,606
Other current assets	1,785	890
Total prepaid expenses and other current assets	$ 15,408	$ 9,073

Intangible Assets - Components

Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 28,751	$ 28,016
Accumulated Amortization and Impairment	(6,910)
Net Carrying Value	$ 21,841	25,890
Accumulated Amortization		$ 2,126
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	8 years	8 years 4 months 24 days
Trade name
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 24,170	$ 24,170
Accumulated Amortization and Impairment	(4,504)
Net Carrying Value	$ 19,666	22,872
Accumulated Amortization		$ 1,298
Trade name \| Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	8 years 4 months 24 days	9 years 2 months 12 days
Other
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 4,581	$ 3,846
Accumulated Amortization and Impairment	(2,406)
Net Carrying Value	$ 2,175	3,018
Accumulated Amortization		$ 828
Other \| Weighted Average
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	4 years 8 months 12 days	2 years 4 months 24 days

Intangible Assets - Amortizatio

Intangible Assets - Amortization of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense related to intangible assets	$ 4,100,000	$ 2,100,000	$ 100,000
Impairment of intangible assets	700,000	0	$ 0
2023	3,434,000
2024	2,694,000
2025	2,560,000
2026	2,452,000
2027 and thereafter	10,701,000
Net Carrying Value	$ 21,841,000	$ 25,890,000

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued Liabilities and Other Liabilities [Abstract]
Payroll	$ 4,999	$ 3,363
Marketing	4,990	3,158
Tax	963	954
Professional services	643	734
Product and shipping	263	2,635
Other accruals	590	1,350
Total accrued liabilities	$ 12,448	$ 12,194

Operating Leases - Additional D

Operating Leases - Additional Details (Details) $ in Thousands	1 Months Ended		2 Months Ended	12 Months Ended
	Jan. 31, 2022 USD ($) ft²	Jan. 31, 2020 USD ($) ft²	Oct. 31, 2022	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Minimum lease payments				$ 5,770
Operating lease costs				1,900	$ 1,800
Variable lease costs				300	300
Operating leases, future minimum payments due				5,307
Operating leases, current, future minimum payments due				1,658	1,365
Operating leases, noncurrent, future minimum payments due				$ 3,649	$ 4,117
New Albany, Ohio
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	62 months	63 months
Area of real estate property \| ft²	24,465	302,880
Minimum lease payments	$ 1,500	$ 7,900
Lessee, operating lease, rent abatement period		3 months	2 months
Rent expense, annual escalation, percent	3%	2.50%
Operating lease, renewal term	5 years	5 years

Operating Leases - Lease Costs

Operating Leases - Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease, payments	$ 1,600	$ 1,500
Operating lease, weighted average remaining lease term	3 years 2 months 12 days
Operating lease, weighted average discount rate, percent	4.70%

Operating Leases - Lease Liabil

Operating Leases - Lease Liability (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 1,876
2024	1,924
2025	1,408
2026	303
2027	259
Gross lease payments	5,770
Less: imputed interest	(463)
Present value of net future minimum lease payments	$ 5,307

Variable Interest Entities (Det

Variable Interest Entities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Current assets	$ 216,595	$ 269,905
Assets	366,341	420,585
Liabilities	54,600	85,966
Net income (loss)	(65,678)	(107,659)	$ (18,114)
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Current assets	7,500	2,200
Assets	7,700	2,200
Liabilities	3,700	3,000
Payments for services	64,200	23,600	12,000
Net income (loss)	$ 9,100	$ (3,300)	$ (1,900)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out liabilities	$ 2,975	$ 1,999
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	169,630	243,771
Earn-out liabilities	2,975	1,999
Total liabilities	2,975	1,999
Fair Value, Recurring \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	25,462	60,617
Earn-out liabilities	0	0
Total liabilities	0	0
Fair Value, Recurring \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	144,168	183,154
Earn-out liabilities	0	0
Total liabilities	0	0
Fair Value, Recurring \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Earn-out liabilities	2,975	1,999
Total liabilities	2,975	1,999
Fair Value, Recurring \| Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	99,566	146,002
Fair Value, Recurring \| Corporate bonds \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Recurring \| Corporate bonds \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	99,566	146,002
Fair Value, Recurring \| Corporate bonds \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Recurring \| Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		29,488
Fair Value, Recurring \| Government bonds \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		0
Fair Value, Recurring \| Government bonds \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		29,488
Fair Value, Recurring \| Government bonds \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		0
Fair Value, Recurring \| Government and government agency
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	33,287
Fair Value, Recurring \| Government and government agency \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0
Fair Value, Recurring \| Government and government agency \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	33,287
Fair Value, Recurring \| Government and government agency \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0
Fair Value, Recurring \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	24,606	59,761
Restricted cash	856	856
Fair Value, Recurring \| Money market funds \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	24,606	59,761
Restricted cash	856	856
Fair Value, Recurring \| Money market funds \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Fair Value, Recurring \| Money market funds \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Fair Value, Recurring \| Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	11,315	7,664
Fair Value, Recurring \| Government bonds \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Fair Value, Recurring \| Government bonds \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	11,315	7,664
Fair Value, Recurring \| Government bonds \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 0	$ 0

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assumptions (Details) - Level 3 - Valuation, Income Approach - Honest Health Limited	Dec. 31, 2022
Revenue risk-adjusted discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.091
Revenue volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.500
Counterparty discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.050

Fair Value Measurements - Chang

Fair Value Measurements - Change in the Fair Value of Earn-out Liabilities (Details) - Earn-out Liability - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,999	$ 0
Change in fair value due to revaluation and service-based vesting	976	10,975
Reclassification to earn-out payable		(42,834)
Ending balance	$ 2,975	1,999
Honest Health Limited
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition		1,208
Apostrophe
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition		$ 32,650

Commitments and Contingencies -

Commitments and Contingencies - Purchase Obligations (Details) $ in Millions	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase obligation	$ 1.4
Purchase obligation, payable in 2023	1.2
Purchase obligation, payable in 2024	$ 0.2

Stockholders' Equity- Common St

Stockholders' Equity- Common Stock (Details)	Dec. 31, 2022 commonStockClass
Share-Based Payment Arrangement [Abstract]
Number of classes of common stock	2

Stockholders' Equity - RSU Rele

Stockholders' Equity - RSU Releases (Details) - RSUs - Common Class A - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock issued during the period (in shares)	2,333,695	1,810,545	0
Share-based payment arrangement, shares withheld for tax withholding obligation (in shares)	701,584	620,759

Stockholders' Equity - 2017 Sto

Stockholders' Equity - 2017 Stock Plan and 2020 Equity Incentive Plan (Details) - USD ($) $ in Millions		1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 01, 2022	Jan. 31, 2022	Jan. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2022
Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, employee stock purchase plans (in shares)				0	0	0	0	393,528
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)								10 years
Common stock issuable under the ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Automatic percentage increase of authorized shares		1%
Employee payroll deductions								$ 0.3
Common stock issuable under the ESPP \| Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			4,000,000					6,047,919
Number of shares available for grant (in shares)								5,654,391
Number of shares benchmark (in shares)		12,000,000
Class A common stock automatically added to the reserve (in shares)	2,047,919
Purchase price of common stock, percent			85%					85%
Maximum \| Common stock issuable under the ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering period			27 months
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			21,000,000					33,101,677
Percentage increase in authorized shares of common stock			5%
Number of shares available for grant (in shares)								10,963,031
Class A common stock automatically added to the reserve (in shares)	10,239,599
Stock Plan, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)			19,000,000
Number of authorized shares transferred between plans (in shares)			1,862,078
Number of shares available for grant (in shares)								0

Stockholders' Equity - 2020 Emp

Stockholders' Equity - 2020 Employee Stock Purchase Plan (Details) - USD ($) $ in Millions		1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 01, 2022	Jan. 31, 2022	Jan. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2022
Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, employee stock purchase plans (in shares)				0	0	0	0	393,528
Common stock issuable under the ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Automatic percentage increase of authorized shares		1%
Employee payroll deductions								$ 0.3
Common stock issuable under the ESPP \| Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			4,000,000					6,047,919
Number of shares benchmark (in shares)		12,000,000
Class A common stock automatically added to the reserve (in shares)	2,047,919
Number of shares available for grant (in shares)								5,654,391
Purchase price of common stock, percent			85%					85%
Common stock issuable under the ESPP \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering period			27 months

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options Narrative (Details)			3 Months Ended	12 Months Ended
Stockholders' Equity - Stock Options Narrative (Details)	Feb. 24, 2022 USD ($) $ / shares shares	Jun. 17, 2020 USD ($) $ / shares shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($) $ / shares	Feb. 28, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)				4 years
Total stock-based compensation expense				$ 42,817,000	$ 67,211,000	$ 5,831,000
Weighted average grant date fair value (in USD per share) \| $ / shares				$ 2.44	$ 6.51	$ 3.49
Intrinsic value of exercises during period				$ 6,300,000	$ 12,600,000	$ 700,000
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value		$ 16,600,000
Exercisable at the end of the period (in shares) \| shares							3,246,139
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount				$ 1,800,000
Options outstanding (in shares) \| shares				1,623,070
Chief Executive Officer \| June 17, 2020 Grant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) \| shares		3,246,139
Awards granted (in USD per share) \| $ / shares		$ 2.43
Acquisition with shares consideration threshold (in USD per share) \| $ / shares		$ 22.99
Chief Executive Officer \| June 17, 2020 Grant Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) \| shares		1,623,070
Awards granted (in USD per share) \| $ / shares		$ 2.43
Acquisition with shares consideration threshold (in USD per share) \| $ / shares		$ 38.31
Chief Executive Officer \| February242022 Grant Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	4 years
Award granted (in shares) \| shares	2,085,640
Awards granted (in USD per share) \| $ / shares	$ 5.01
Grant date fair value	$ 3,800,000
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount				$ 2,600,000
Share based payment arrangement option share price trigger (in USD per share) \| $ / shares	$ 10
Share based payment arrangement option threshold trading (in days)	$ 20
Share-based payment arrangement, option, threshold consecutive trading days (in days)	30
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount				$ 22,700,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)				10 years
Stock options \| Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition				1 year 3 months 14 days
Stock options \| Chief Executive Officer \| June 17, 2020 Grant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense			$ 11,300,000
Stock options \| Chief Executive Officer \| February242022 Grant Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards vesting rights, percentage	25%
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition				3 years 1 month 24 days
Stock options \| New Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)				4 years
Award vesting rights, monthly percentage				2.083%
Stock options \| New Employee \| Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)				1 year
Awards vesting rights, percentage				25%
Stock options \| Current Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)				4 years
Award vesting rights, monthly percentage				2.083%
Stock options \| Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition				2 years 7 months 24 days

Stockholders' Equity - Weighted

Stockholders' Equity - Weighted Average Fair Value Assumptions (Details) - Stock options	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 7 days	5 years 11 months 8 days	5 years 11 months 8 days
Expected volatility	48%	58.60%	62.30%
Risk-free interest rate	2%	0.90%	0.50%
Expected dividend yield	0%	0%	0%

Stockholders' Equity- Option Ac

Stockholders' Equity- Option Activity (Details) - Employee, excluding CEO - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Shares
Beginning balance (in shares)	10,401
Granted (in shares)	6,321
Exercised (in shares)	(1,728)
Forfeited and expired (in shares)	(544)
Ending balance (in shares)	14,450	10,401
Exercisable at the end of the period (in shares)	8,389
Weighted Average Exercise Price
Beginning balance (in USD per share)	$ 4.01
Granted (in USD per share)	5.10
Exercised (in USD per share)	1.42
Forfeited and expired (in USD per share)	6.97
Ending balance (in USD per share)	4.68	$ 4.01
Exercisable at the end of the period (in USD per share)	$ 3.81
Weighted Average Contractual Period (in Years)
Outstanding balance (in years)	7 years 11 months 23 days	7 years 8 months 23 days
Exercisable at the end of the period (in years)	7 years 1 month 28 days
Aggregate Intrinsic Value
Outstanding balance	$ 35,771	$ 37,868
Exercisable at the end of the period	$ 28,509

Stockholders' Equity - Exercise

Stockholders' Equity - Exercise Price Range of Options Outstanding and Exercisable (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Options Outstanding
Shares (in shares)	14,450	10,401
Options Exercisable
Shares (in shares)	8,389	8,974
$0.06 – 0.40
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 0.06	$ 0.06
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 0.40	$ 0.40
Options Outstanding
Shares (in shares)	1,830	2,309
Weighted Average Remaining Contractual Life (in Years)	5 years 2 months 15 days	5 years 7 months 20 days
Options Exercisable
Shares (in shares)	1,830	2,308
Weighted Average Remaining Contractual Life (in Years)	5 years 2 months 15 days	5 years 7 months 20 days
1.55 – 1.75
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 1.55	$ 1.55
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 1.75	$ 1.75
Options Outstanding
Shares (in shares)	959	2,120
Weighted Average Remaining Contractual Life (in Years)	6 years 5 months 4 days	7 years 4 months 2 days
Options Exercisable
Shares (in shares)	959	2,006
Weighted Average Remaining Contractual Life (in Years)	6 years 5 months 4 days	7 years 4 months 2 days
2.43 – 3.11
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 2.43	$ 2.43
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 3.11
Options Outstanding
Shares (in shares)	3,037	3,242
Weighted Average Remaining Contractual Life (in Years)	7 years 6 months	8 years 5 months 1 day
Options Exercisable
Shares (in shares)	2,921	3,241
Weighted Average Remaining Contractual Life (in Years)	7 years 5 months 1 day	8 years 5 months 1 day
5.01 – 6.82
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 5.01
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 6.82
Options Outstanding
Shares (in shares)	6,190
Weighted Average Remaining Contractual Life (in Years)	9 years 2 months 15 days
Options Exercisable
Shares (in shares)	977
Weighted Average Remaining Contractual Life (in Years)	9 years 2 months 1 day
8.13 – 9.41
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 8.13	$ 8.13
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 9.41	$ 9.41
Options Outstanding
Shares (in shares)	1,569	1,756
Weighted Average Remaining Contractual Life (in Years)	8 years 1 month 17 days	8 years 9 months 25 days
Options Exercisable
Shares (in shares)	1,301	1,291
Weighted Average Remaining Contractual Life (in Years)	8 years 14 days	8 years 6 months 14 days
12.21 – 15.17
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share)	$ 12.21	$ 12.21
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share)	$ 15.17	$ 15.17
Options Outstanding
Shares (in shares)	865	974
Weighted Average Remaining Contractual Life (in Years)	8 years 2 months 8 days	9 years 3 months 10 days
Options Exercisable
Shares (in shares)	401	128
Weighted Average Remaining Contractual Life (in Years)	8 years 10 days	9 years 7 days

Stockholders' Equity - RSUs Nar

Stockholders' Equity - RSUs Narrative (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2022	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		4 years
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		4 years
Granted (in shares)		10,536,000	45,297
Vested (in shares)		2,294,000
Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount		$ 59.1
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition		3 years 7 days
RSUs \| Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		1 year
Awards vesting rights, percentage		25%
RSUs \| Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		15,099
Earn Out Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)		317,539
Earn Out Restricted Stock Units \| Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		476,308
Earn Out Restricted Stock Units \| Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	4,431	1,477
Parent Warrant Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)		6,319
Parent Warrant Restricted Stock Units \| Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		9,478
Parent Warrant Restricted Stock Units \| Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	88	30

Stockholders' Equity - RSUs Act

Stockholders' Equity - RSUs Activity (Details) - RSUs - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020
Shares
Beginning balance (in shares)	3,982,000
Granted (in shares)	10,536,000	45,297
Vested (in shares)	(2,294,000)
Forfeited and expired (in shares)	(623,000)
Ending balance (in shares)	11,601,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 11.55
Granted (in dollars per share)	4.97
Vested (in dollars per share)	8.86
Forfeited and expired (in dollars per share)	8.05
Ending balance (in dollars per share)	$ 6.40

Stockholders' Equity - Vendor W

Stockholders' Equity - Vendor Warrants Narrative (Details) - Vendor Warrants $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock outstanding and exercisable (in shares)	462,335
Exercisable and outstanding, weighted average exercise price (in usd per share) \| $ / shares	$ 1.75
Exercisable and outstanding, weighted average remaining contractual terms	7 years 3 days
Exercisable and outstanding, aggregate intrinsic value \| $	$ 2,200
Beginning balance (in shares)	462,335
Exercisable at the end of period (in shares)	462,335
Earn-Out Consideration
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares)	45,225
Pre Merger Debt Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock outstanding and exercisable (in shares)	98,723
Exercisable and outstanding, weighted average exercise price (in usd per share) \| $ / shares	$ 6.96
Exercisable and outstanding, weighted average remaining contractual terms	6 years 8 months 15 days
Exercisable and outstanding, aggregate intrinsic value \| $	$ 0
Beginning balance (in shares)	98,723
Exercisable at the end of period (in shares)	98,723

Stockholders' Equity - Stock Su

Stockholders' Equity - Stock Subject to Vesting and Earn-out Share Liability (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Jul. 31, 2021	Jun. 30, 2021	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Restricted Stock \| Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount			$ 3.6
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			2 years 4 months 9 days
Restricted Stock \| Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount			$ 12.1
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			1 year 6 months
Restricted Stock \| Employee \| Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		4 years
Restricted Stock \| Employee \| Honest Health Limited \| Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		1 year
Awards vesting rights, percentage		25%
Restricted Stock \| Employee \| Honest Health Limited \| Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		447,553
Aggregate grant date fair value		$ 5.5
Restricted Stock \| Employee \| Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Restricted Stock \| Employee \| Apostrophe \| Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	6 months
Awards vesting rights, percentage	17%
Restricted Stock \| Employee \| Apostrophe \| Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	2,332,557
Aggregate grant date fair value	$ 24.2

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock-Based Compensation Expense for Employees and Nonemployees (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 42,817,000	$ 67,211,000	$ 5,831,000
Share-based payment arrangement, amount capitalized	600,000	700,000	0
Marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	4,648,000	9,664,000	1,172,000
Operations and support
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2,684,000	2,735,000	155,000
Technology and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	4,327,000	4,481,000	269,000
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 31,158,000	$ 50,331,000	$ 4,235,000

Stockholders' Equity - Acquisit

Stockholders' Equity - Acquisitions (Details) - Common Class A - shares		1 Months Ended
	Jun. 11, 2021	Jul. 31, 2021
Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock for acquisition of businesses (in shares)	177,327
Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock for acquisition of businesses (in shares)		5,742,378

Related-Party Transactions (Det

Related-Party Transactions (Details) - Affiliated Entity - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 3.6	$ 3.5	$ 3.4
Identity Verification Services
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 1	$ 0.7
Identity Verification Services \| Maximum
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party			$ 0.1

Basic and Diluted Net Loss pe_3

Basic and Diluted Net Loss per Share - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Dividends, common stock	$ 0	$ 0	$ 0
Antidilutive securities excluded from computation of earnings per share (in shares)		0
Common Class A Redeemable Stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Shares subject to redemption (in shares)			165,133
Common Redeemable Stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0

Basic and Diluted Net Loss pe_4

Basic and Diluted Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net loss attributable to common stockholders	$ (65,678)	$ (107,659)	$ (18,114)
Denominator:
Weighted average shares outstanding, basic (in shares)	204,516,120	186,781,537	35,353,809
Weighted average shares outstanding, diluted (in shares)	204,516,120	186,781,537	35,353,809
Basic net loss per share (in USD per share)	$ (0.32)	$ (0.58)	$ (0.51)
Diluted net loss per share (in USD per share)	$ (0.32)	$ (0.58)	$ (0.51)
Common Class A
Numerator:
Net loss attributable to common stockholders	$ (62,988)	$ (103,082)	$ (14,558)
Denominator:
Weighted average shares outstanding, basic (in shares)	196,138,497	178,840,009	28,412,457
Weighted average shares outstanding, diluted (in shares)	196,138,497	178,840,009	28,412,457
Basic net loss per share (in USD per share)	$ (0.32)	$ (0.58)	$ (0.51)
Diluted net loss per share (in USD per share)	$ (0.32)	$ (0.58)	$ (0.51)
Common Class V
Numerator:
Net loss attributable to common stockholders	$ (2,690)	$ (4,577)
Denominator:
Weighted average shares outstanding, basic (in shares)	8,377,623	7,941,528
Weighted average shares outstanding, diluted (in shares)	8,377,623	7,941,528
Basic net loss per share (in USD per share)	$ (0.32)	$ (0.58)
Diluted net loss per share (in USD per share)	$ (0.32)	$ (0.58)
Common Class F
Numerator:
Net loss attributable to common stockholders			$ (3,556)
Denominator:
Weighted average shares outstanding, basic (in shares)			6,941,352
Weighted average shares outstanding, diluted (in shares)			6,941,352
Basic net loss per share (in USD per share)			$ (0.51)
Diluted net loss per share (in USD per share)			$ (0.51)

Basic and Diluted Net Loss pe_5

Basic and Diluted Net Loss per Share - Schedule of Excluded Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)		0
Common stock issued for exercise of stock options subject to nonrecourse promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	874,312	16,514,103
Common stock issued for early exercise of stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	70,257	196,431	99,548
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	4,858,176	90,268,364
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	20,470,391	16,345,661	11,509,177
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	8,778,890	4,081,026	114,624
Warrants \| Common Class A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	561,058	4,778,003	1,767,451
Warrants \| Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	931,668
Common stock issued subject to vesting
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2,027,852	1,419,613	0
Common stock issuable under the ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	603,603	136,538	0

Income Taxes - Loss Before Prov

Income Taxes - Loss Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Domestic	$ (62,539)	$ (109,393)	$ (16,934)
Foreign	(3,170)	(1,402)	(1,053)
Loss before income taxes	$ (65,709)	$ (110,795)	$ (17,987)

Income Taxes - Components Attri

Income Taxes - Components Attributable to the Provision for Income Taxes (Details) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal	$ 0	$ 0	$ 0
State	563	252	127
Foreign	0	0	0
Total current provision	563	252	127
Deferred:
Federal	(339)	(2,280)	0
State	(110)	(966)	0
Foreign	(145)	(142)	0
Total deferred benefit	(594)	(3,388)	0
Total (benefit) provision for income taxes	$ (31)	$ (3,136)	$ 127

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Tax benefit at federal statutory rate	$ (13,799)	$ (23,267)	$ (3,777)
State taxes, net of federal benefits	(609)	(3,498)	(364)
Transaction costs	(731)	369	0
Stock-based compensation	3,897	2,018	698
Warrants and earn-outs	(15)	(1,710)	(403)
Non-deductible officers' compensation	2,881	8,352	0
Change in valuation allowance	7,794	15,971	3,948
Other, net	551	(1,371)	25
Total (benefit) provision for income taxes	$ (31)	$ (3,136)	$ 127

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 67,214	$ 61,640
Accrued expenses and reserves	1,952	1,245
Stock-based compensation	4,079	4,130
Inventory	2,338	2,214
Other intangibles	487	49
Deferred revenue	17	0
Operating lease liabilities	1,382	1,441
Other deferred tax assets	553	456
Total gross deferred tax assets	78,022	71,175
Less valuation allowance	(69,357)	(61,328)
Total deferred tax assets	8,665	9,847
Deferred tax liabilities:
Other intangibles	(5,623)	(6,933)
Fixed assets	(1,722)	(2,088)
Operating lease right-of-use assets	(1,285)	(1,343)
Other deferred tax liabilities	(70)	(112)
Total deferred tax liabilities	(8,700)	(10,476)
Net deferred tax liabilities	$ (35)	$ (629)

Income Taxes - Additional Detai

Income Taxes - Additional Details (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Contingency [Line Items]
Valuation allowance, deferred tax asset, increase (decrease), amount	$ 8	$ 16.8
Operating loss carryforwards, domestic	245.6
Operating loss carryforwards, state	204.2
Operating loss carryforwards, foreign	5.9
Apostrophe
Income Tax Contingency [Line Items]
Valuation allowance, deferred tax asset, release		$ 3.1
Federal
Income Tax Contingency [Line Items]
Operating loss carryforwards, not subject to expiration	238.8
State
Income Tax Contingency [Line Items]
Operating loss carryforwards, not subject to expiration	19.8
Foreign
Income Tax Contingency [Line Items]
Operating loss carryforwards, not subject to expiration	$ 5.9